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ABSTRACT OF THE DISSERATION

SEX DIFFERENCES IN CELL DEATH AND NUCLEAR HORMONE
RECEPTORS IN CORTICAL EXPLANTS
Estrogens, such as the biologically active 17-! estradiol (E2) have many
actions in the male and female brain. Not only does E2 regulate reproductive
behavior in adults, it organizes and activates the brains of younger animals in a
sex-specific manner. In addition, many human studies have shown E2 to provide
protection against a variety of neurological disorders, including stoke. These
studies have been controversial and depend largely on the type and timing of
hormone replacement. Animal studies are much less controversial and clearly
demonstrate a neuroprotective role for E2 following ischemic brain injury.
Because much of E2 neuroprotection requires sex steroid hormone receptors, it
is essential to understand expression patterns of these receptors. For the
current studies, I evaluated estrogen receptor alpha (ER !), estrogen receptor
beta (ER ") and androgen receptor (AR) expression in the cortex. It is known
that these receptors change in expression at several times in an animal’s life
span including during early postnatal development and following ischemic brain
injury. Here I used an in vitro cortical explant model to further examine how
these receptors change both during development and following injury. This in
vitro model is important because it provides a way to investigate changes in
receptor expression pattern in the cortex without input from other brain regions.
In addition to characterizing this model, I also evaluated the contribution of E2 to
changes in receptor expression and on cell death following injury in the explants.
To begin to decipher mechanisms for E2 mediated neuroprotection, I added
antagonist for each of the receptors before and after injury. In each these
experiments, I also examined potential sex differences by separating the female
and male brains before I cultured the explants. Overall, these experiments
showed that cortical explants are a good in vitro model. Here we found that E2
was protective in female, but not male cortical explants following injury.
However, the exact mechanisms of E2-mediated neuroprotection are still to be
deciphered.

KEYWORD: Sex Differences, Estrogen, Neuroprotection, Sex Steroid
Hormones, Ischemia
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CHAPTER 1: GENERAL INTRODUCTION
Overview
Estrogens influence sexual differentiation and exert a multitude of effects
throughout life in both females and males (McCarthy 2009; Wright, Schwarz et al.
2010; Eliot 2011). During perinatal development, estrogens organize neuronal
circuits in the brain that regulate gonadal secretions and sexual receptivity.
Estrogens also have non-reproductive roles in the brain during development,
such as influencing spine density and synaptogenesis, which plays a role in
learning and memory (McEwen, Coirini et al. 1991; McEwen and Woolley 1994;
McEwen, Gould et al. 1995; Woolley 1998). Following development, estrogens
can be neuroprotective and neurotrophic in animal models of disease (Dubal,
Wilson et al. 1999; Dubal and Wise 2001; Garcia-Segura, Azcoitia et al. 2001;
Wise 2003). The level of circulating estrogens in the brain influences the amount
of brain damage following an experimental stroke, middle cerebral artery
occlusion (MCAO). For example, in animals with lower levels of circulating
estrogens such as gonadectomized females (Simpkins, Rajakumar et al. 1997;
Dubal, Kashon et al. 1998; Toung, Traystman et al. 1998; Rusa, Alkayed et al.
1999) and males (Toung, Traystman et al. 1998), there is a larger amount of cell
death following MCAO. Pretreatment with even low doses of the biologically
active, 17!-estradiol (E2) is sufficient to exert dramatic protection from brain
injury in both female (Dubal, Kashon et al. 1998; Dubal and Wise 2001) and male
rats (Toung, Traystman et al. 1998).
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In humans, the role of hormone replacement is not as clear. In fact, some
clinical studies found that estrogens were not beneficial at all (Wilson, Garrison et
al. 1985; Grodstein, Stampfer et al. 1996; Petitti, Sidney et al. 1998; Anderson,
Limacher et al. 2004), while other studies did report benefits following stroke
(reviewed in (Behl 2002; McCullough and Hurn 2003)). The discrepancies
between different studies may be explained by differences in the timing of
estrogen replacement and the age of women included in the studies. Animal
studies are much less controversial and provide a simpler model to study the
mechanisms of neuroprotection by E2 following ischemic brain injury.
A common model of focal ischemic stoke is MCAO which causes initial
necrotic cell death in the striatum followed by apoptotic cell death in the cerebral
cortex. In female rodents, treatment with E2 attenuates this cell death in the
cortex via an estrogen receptor alpha (ER!)-dependent mechanism. In males,
treatment with E2 can be protective, but the mechanism for E2 action is less
clear. Another model of ischemic injury is treatment with a combination of 2deoxyglucose and potassium cyanide (2DG/KCN) in cortical explants. 2DG/KCN
blocks oxidative phosphorylation and glycolysis, which causes cell death that in
some circumstances, can be attenuated by E2 treatment (Wilson, Dubal et al.
2000; Wise, Dubal et al. 2000; Wilson, Liu et al. 2002). There are several
advantages of using this cortical explant model over using the whole animal
(MCAO) or isolated neuron cultures. Explant cultures are a simplified
environment in which pharmacological manipulations that are difficult or
impossible in whole animal are possible. In explants, the cortex is isolated from
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other regions of the brain, which allows us to examine innate cell responses that
may indicate a sex difference in the way the cortex is originally organized during
development. Additionally, this model is superior to isolated neurons because
explant cultures maintain cytoarchitectural organization and neuronal/glial
relationships. The following studies will employ this cortical explant model to
investigate innate sex differences in the way steroid hormone receptors respond
during development and following injury.
The studies described in this dissertation were designed to test the overall
hypothesis that steroid hormone receptor expression, in response to injury, is
different in the female and male brain. Specifically first I predicted that changes
in sex steroid hormone receptor expression that occur during early postnatal
development in the rodent cortex would also be maintained in the cortical explant
model. If sex steroid hormone receptors do increase and/or decrease across
development in culture in a similar pattern as we see in the cortex, it would
suggest that regulation of these receptors is preprogrammed in the cortex and
does not require input from other brain regions. Secondly, I predicted that
2DG/KCN treatment would increase cell death in cortical explants and that E2
treatment would attenuate this cell death in sex-specific manner. If E2-mediated
neuroprotection following injury is sex-specific in explants, it would suggest that
the mechanisms for E2-mediated neuroprotection are sex-specific and most
likely innate to the cortex. Thirdly, I predicted that 2DG/KCN-induced injury would
change expression of some or all of these steroid hormone receptors in a sexspecific manner. If there is a sex difference in the response of some or all of
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these receptors, it may account for the sex-specific protection by E2 in females.
Lastly, I predicted that blocking some or all of these receptors would increase
ischemia-induced cell death and remove the E2 neuroprotection seen in female
explants. If disruption of one of the receptors does change the amount of cell
death or disrupts the E2-mediated neuroprotection, it would suggest that E2 is
working via that receptor in our model.
Below I have included a general literature review to describe some of the
studies that provide that basic groundwork for the experiments included in these
studies.
General Literature Review
Estrogens
Estrogens are the rudimentary female sex hormone named for their
significance in the estrous cycle. Estrogen was first discovered by Allen Edgar in
1923. The structure was independently isolated in 1929 by both Adolf Butenandt
and Edward Adelbert. Estrogen has three isoforms: estrone (E1), estradiol (E2)
and estriol (E3) (Figure 1.1) (Watson, Jeng et al. 2008). E1 is primarily made
from adipose tissue, E2 from gonadal tissue and E3 in pregnancy (Berne RM
2004). E2, 17-! estradiol, is the most abundant and biologically active form of
estrogen. Estrogen is a steroid hormone and a cholesterol derivative.
Cholesterol or acetyl-coenzyme A (acetyl-CoA) is taken into the cell by
endocytosis and transported to the inner mitochondrial membrane by
steroidogenic acute regulatory protein (StAR), where cholesterol is converted to
pregnenolone

!

4

A.

Estrone (E1)

B.

Estradiol (E2)

C.

Estriol (E3)
Figure 1.1. Chemical structure of estrogens. Modified from (Watson, Jeng et
al. 2008) (A). Estrone also known as E1 has one hydroxyl group (OH). (B).
Estradiol (E2), the most biologically active form of estrogen, has two hydroxyl
groups and (C) Estriol has three hydroxyl groups and is also known as E3.
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(Berne RM 2004; Kim, Kang et al. 2004). In the ovaries in females and the testis
in males, cholesterol is converted into estrogens through a conglomerate of 6 or
7 enzymatic reactions (Berne RM 2004; McCarthy 2009). Estrogens can also be
made extra-gonadally in adipose tissue (Simpson, Zhao et al. 1997), bone
(Bruch, Wolf et al. 1992; Simpson, Rubin et al. 1999), heart (Taves, GomezSanchez et al. 2011) and the brain (Simpson, Rubin et al. 1999; Zwain and Yen
1999; Ibanez, Guennoun et al. 2003; Hojo, Hattori et al. 2004; Tsutsui 2008;
Mirzatoni, Spence et al. 2010; Fester, Prange-Kiel et al. 2011). In rodents,
estrogen is synthesized in the brain during development (Ibanez, Guennoun et
al. 2003; Tsutsui 2008; Nagarajan, Tsai et al. 2011) and also after injury
(Mirzatoni, Spence et al. 2010). Astrocytes (Garcia-Segura, Wozniak et al. 1999)
and neurons (Beyer 1999; King, Manna et al. 2002; Schaeffer, Meyer et al. 2010)
contain the genes necessary to synthesize E2. While it is in debate if all areas of
the brain are capable of local E2 synthesis from cholesterol (de novo
neurosteroidogenesis), the cortex and hippocampus do have important enzymes
such as StAR and aromatase, which suggests neurosteroidogenesis does occur
(Zwain and Yen 1999; King, Manna et al. 2002; Fester, Ribeiro-Gouveia et al.
2006; Fester, Prange-Kiel et al. 2011). The fact that steroidogenesis occurs
locally in certain brain regions highlights the evolutionary role of steroids in the
brain even though not all areas are considered to be involved reproduction.
Estrogen is important for the organization and activation of sex specific
characteristics during early development in humans and animals. Estrogens
influence the growth, differentiation and functioning in many target tissues,
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including the mammary gland, uterus, ovary, testis, and prostate (Kuiper,
Carlsson et al. 1997). Estrogens also play an important role in bone
maintenance and in the cardiovascular system (Kuiper, Carlsson et al. 1997;
Simpson, Rubin et al. 1999; Baker, Meldrum et al. 2003), along with being
neuroprotective and neurotrophic in the brain (Dubal, Wilson et al. 1999; Wise,
Dubal et al. 2000; Dubal and Wise 2001; Garcia-Segura, Azcoitia et al. 2001;
Wise, Dubal et al. 2001; Wise, Dubal et al. 2001; Wise 2003; Marin, Guerra et al.
2005). In the rodent hippocampus, estrogen treatment increases neurite length,
spine density, and synaptogenesis (Gould, Woolley et al. 1990; Woolley 1998;
McEwen and Alves 1999; McEwen, Tanapat et al. 1999; Gould, Tanapat et al.
2000).
Initially, the actions of gonadal hormones were thought to be neuronal
because of the high level of receptor expression in neurons (Simerly, Chang et
al. 1990; Brown, Sharma et al. 1995; Shughrue, Lane et al. 1997). However,
astrocytes and microglia also respond to gonadal hormones (Garcia-Estrada, Del
Rio et al. 1993; Jones, Kinderman et al. 1997; Garcia-Estrada, Luquin et al.
1999; Bruce-Keller, Keeling et al. 2000). Specifically, following injury astrocytes
were shown to express estrogen receptor alpha (ER!) and microglia to express
androgen receptor (AR) (Garcia-Ovejero, Veiga et al. 2002). This indicates that
part of the response to injury in cells of the brain is to up-regulate expression of
sex steroid hormone receptors.
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Sex Steroid Hormone Receptors
Estrogens can have both genomic and non-genomic actions on target
tissues by binding to the well-characterized steroid hormone receptors, estrogen
receptor alpha (ER!) and estrogen receptor beta (ER") (Green, Kumar et al.
1986; Koike, Sakai et al. 1987; Kuiper, Enmark et al. 1996; Berne RM 2004).
Androgens have important actions by binding to Androgen receptor (AR). ER!
and ER" are not splice variants, but are completely separate genes. ER!, also
known as ERS1, is located on chromosome 6 in humans, 10 in mice and 1 in
rats. ER", also known as ERS2, is located on chromosome 14 in humans, 12 in
mice and 6 in rats (Figure 1.2) (Saunders 1998; Bain, Heneghan et al. 2007).
Although both receptors share a similar DNA binding domain, their overall
sequence homology is low and they are generally expressed in different tissues
(Katzenellenbogen, O'Malley et al. 1996; Shughrue, Lane et al. 1997; Saunders
1998; Denger, Reid et al. 2001; Berne RM 2004; Bain, Heneghan et al. 2007).
Another important sex steroid hormone receptor associated with sex
differences is the androgen receptor (AR). Androgen receptor is also known as
NR3C4 because it is a member of the 3rd nuclear receptor subfamily group C
member 4 (Lu, Wardell et al. 2006). AR primarily mediates is actions with
androgens (Roy, Lavrovsky et al. 1999) and is located on the X chromosome
(Chang, Kokontis et al. 1988; Trapman, Klaassen et al. 1988; Chang, Kokontis et
al. 1990). ER!, ER" and AR are steroid hormone receptors located not only in
the nucleus, but also in the plasma membrane, cytosol and mitochondria (Speroff
2000; Gonzalez, Cabrera-Socorro et al. 2007). AR expression is localized with
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A.

NTD DBD Hinge
ER!

Percent Homology (%)

ER"

LBD

CTD

A/B

C

D

E

F

17.5
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30

59.1

A/B

C

D

E

17.9
F

B.

Chromosome
Human

Mouse

Rat

ER!

6

10

1

ER"

14

12

6

Figure 1.2. Structure of estrogen receptors. (A). Estrogen receptor alpha
(ER!), top schematic, and estrogen receptor beta (ER"), bottom schematic.
Steroid hormone receptors are all composed of domains A-F, diagramed above.
A/B is the N-terminal domain (NTD), C is the highly conserved DNA Binding
Domain (DBD), D a flexible hinge region, E is the C-terminal Ligand Binding
Domain (LBD) and F is an additional C terminal domain of unknown function.
Percent homology between human ER! and human ER" located between the
two protein domain schematics. (B). Location of the ER! and ER" genes in
human, mouse and rat.
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ER! and ER" expression in many areas of the brain, specifically the cortex and
hypothalamus (Patchev, Schroeder et al. 2004).
Sex steroid hormones exert genomic actions on target tissues by first
binding to their receptors and homo or heterodimerizing (Murdoch and Gorski
1991; Berne RM 2004). Specifically, estrogen binds to ER!, ER" or both (homo
or heterdimerizing) and initiates transcription by attaching to an estrogen
response element (ERE) (5’GGTCAXXXTGACC3’) as a transcription factor
(Murdoch and Gorski 1991; Berne RM 2004) (Green, Kumar et al. 1986; Koike,
Sakai et al. 1987; Kuiper, Enmark et al. 1996; Berne RM 2004), Figure 1.3.
Many genes utilize ER as a transcription factor to regulate their expression
(Murdoch and Gorski 1991; McEwen and Alves 1999). The dimerized ERs can
also bind to transcription factors such as activator protein (AP)-1 and NF-kB and
initiate transcription factor cross talk through enhancer sequences, non-ERE
signaling (Porter, Saville et al. 1997; Teyssier, Belguise et al. 2001), Figure 1.3.
E2 can also act through non-genomic pathways. The non-genomic actions
include membrane initiated signaling pathways that are activated not only by ER
! and ER ", but by G-protein-coupled receptors and ligand-gated ion channels
(Watson, Jeng et al. 2008; Roman-Blas, Castaneda et al. 2009; Liu, Zhang et al.
2012). Estradiol has been shown to induce phosphorylation of extracellular
signal-regulated kinase (ERK1/2) (Singh, Setalo et al. 1999; Setalo, Singh et al.
2002; Liu, Zhang et al. 2012). ERK is a part of the mitrogen-activated protein
(MAP) kinase pathway (Singer, Figueroa-Masot et al. 1999; Watson, Jeng et al.
2008). These kinases regulate a number of cellular responses one of which is
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ER’s
Nucleus
ER ER

ER ER
TF TF

ERE-mediated
transcription

Transcription factor
cross-talk

Figure 1.3. Intracellular estradiol signaling. Modified from (Roman-Blas,
Castaneda et al. 2009) 17-! estradiol, E2, (pink rectangles) can cross the cell
membrane and bind to estrogen receptors, ER (yellow receptors). These ERs
diamerize and initiate transcription by binding to estrogen response elements
(ERE’s) or binding to transcription factors such as activator protein (AP)-1 and
NF-kB and initiate transcription factor cross talk, ERE signaling.
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cell death (Lee and McEwen 2001; Murphy and Blenis 2006).
Another second messenger signaling pathway that can be activated by E2
is the serine/threonine protein kinase, AKT, through the phosphatidylinositide
3’OH kinase (PI3 K) (Datta, Brunet et al. 1999; Wilson, Liu et al. 2002). ERs can
be activated through phosphorylation in the absence of E2 by growth factors
such as insulin-like grown factor (IGF)-1 or epidermal growth factor (EGF) or
through PI3K/Akt or PKC/MAPK. Activation of one or more of these signaling
cascades by E2 can promote cell survival.

Regulation of steroid hormone receptors
Steroid hormone receptor expression is dynamic throughout an animal’s
lifespan. In rodents, ER! mRNA expression changes across development in the
cortex (Prewitt and Wilson 2007). ER! mRNA is high during early postnatal
development when organization and sexual differentiation occurs in the brain
(Zhang, Chang et al. 2000). Its expression is significantly decreased after
PND10 and virtually absent in the uninjured adult cortex (Prewitt and Wilson
2007). ER! mRNA is concentrated in the cerebral cortex and hippocampus and
other brain regions that indicate non-reproductive actions of E2 (Shughrue, Lane
et al. 1997; Mitra, Hoskin et al. 2003). It is important to note that while both ER"
and ER! are expressed in the hippocampus, a region of the brain involved in
cognitive function (Bliss and Collingridge 1993), only ER! is expressed in the
adult rodent cortex (Shughrue, Lane et al. 1997). ER" and ER! mRNAs are
expressed throughout the human brain as well, but with distinctive patterns
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(Osterlund, Grandien et al. 2000; Osterlund, Keller et al. 2000; Gonzalez,
Cabrera-Socorro et al. 2007). It is not fully known which ER is responsible for
mediating the effects of estrogen on cognition. However, accumulating evidence
from knock out (KO) mice supports an important role for ER!. ER! KO micetreated with E2 show impairments in acquisition of a spatial reference memory,
implicating a role for ER! in hippocampus dependent cognition (Rissman, Heck
et al. 2002). Interestingly, AR expression also changes by increasing across
early postnatal development in the cortex (Nunez, Huppenbauer et al. 2003) and
in the adult cortex depending on the different phases of the estrus cycle (Feng,
Weijdegard et al. 2010).

Women’s Health Initiative
E2 has been shown to be beneficial for memory and cognition, and also
reduces the incidence and severity of neurodegenerative diseases including
Alzheimer’s Disease and stroke (Paganini-Hill and Henderson 1994; Sherwin
1994; Paganini-Hill 1995; Henderson, Watt et al. 1996; Paganini-Hill and
Henderson 1996; Sherwin 1996; Henderson 1997; Kawas, Resnick et al. 1997;
Paganini-Hill 1997; Sherwin 1997; Green, Perez et al. 2000; Wise, Dubal et al.
2001; Wise, Dubal et al. 2001; Wise, Dubal et al. 2001; Suzuki, Brown et al.
2006; Chen, Cammarata et al. 2009). For example, pre-menopausal women
have a lower incidence of stroke than men, but this discrepancy between men
and women dissipates following menopause, presumably because of a decrease
in protective E2. This population of postmenopausal women is increasing
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because the average age of menopause has remained fixed at 51, while the
average life expectancy in the US has increased to over 80 years (Suzuki, Brown
et al. 2006). Thus, many women will spend a large portion of their lives in a
hypo-estrogenic state. Many studies have been conducted to explore different
hormone replacement regimes to counteract the negative effects of the loss of
estrogen following menopause. Hormones and estrogen replacement therapies
have received a great deal of attention in the popular media due to the early
termination of the Women’s Health Initiative (WHI). The WHI found an increased
risk of cardiovascular complications, stroke and breast cancer in women using
hormone replacement therapy (Rossouw 2002); however, part of this
discrepancy can be explained by the timing of estrogen replacement and the age
of women included in the studies (Sherwin 2009; Wise, Suzuki et al. 2009).
Animal studies are much less controversial and clearly demonstrate a
neuroprotective role for E2 following ischemic brain injury. Taken together these
data indicate complex actions of estrogen and hormone replacement therapies
that warrant further investigations. An important aspect of this investigation will
be to determine how E2 acts through its estrogen receptors and how these
receptors are regulated after injury.

Sex Differences in Neurodegenerative Diseases
Neurodegenerative diseases appear to be more robustly present in
individuals later in life, when sex steroids have started to decline. Estrogen
declines dramatically in women during menopause, while testosterone does also
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decline with age but not as significantly. Many diseases that affect the brain are
more prominent in one sex verses the other. The prefrontal cortex (PFC) is
believed to play a role in these diseases. The PFC is rich in steroid hormones
receptors (Bixo, Backstrom et al. 1995) and associated with sex specific
responses to stress (Shansky, Glavis-Bloom et al. 2004; Bland, Schmid et al.
2005). Neuropsychatiric disorders including depression and anxiety are more
prominent in females while alcohol induced dependencies, schizophrenia, autism
and attention deficit disorders have a higher incidence in males (Davies and
Wilkinson 2006). While Parkinson’s Disease (Shulman and Bhat 2006) appears
to be more prominent in the male population, Alzheimer’s Disease (Pinkerton and
Henderson 2005) and stroke have a higher incidence in females. The
mechanisms that cause the sex differences in these diseases may be
confounding. Women have fewer cortical neurons (de Courten-Myers 1999;
Rabinowicz, Petetot et al. 2002) and experience a severe decrease in hormones
with menopause. Since cell death occurs in a large number of
neurodegenerative diseases, women may be more at risk of neuronal damage
because of their lower number of cortical neurons to start with. Women also
have a longer life expectancy than men (U.S Census 2012), which may increase
their risk of developing diseases. The hormonal milieu in women and men is
different along with their time frame of hormonal production. For example,
estrogen may elicit protective effects in women and not men due to differences in
hormone concentration and action (Vina, Gambini et al. 2011).
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Neurodegenerative diseases have many parallel cellular responses in
their histology and mechanisms of action. By definition a neurodegenerative
disease is a result of loss of neuronal function resulting in ataxia or memory loss
(dementia) (Ross and Poirier 2004). Themes that are common among these
diseases include protein aggregation, calcium deregulation, oxidative stress,
neural inflammation, excitotoxicity, neurotransmitter loss, and altered steroid
genesis, and interestingly enough they seem to be interwoven. One theme leads
to the initiation of another until a complete cascade that amplifies the original
theme has begun. For example, protein aggregation causes oxidative stress and
inflammation, which leads to excitotoxicity and calcium deregulation. The
accumulation of these cascades leads to cell dysfunction by altering the signaling
pathways, which then leads to additional protein aggregation. The integration of
these common themes leads to apoptosis or necrosis of the neurons in various
brain regions in disease states.
Estrogens can affect the many themes involved in neurodegenerative
diseases. Estrogen not only has genomic and non-genomic effects by
decreasing pro-apoptotic and increasing anti-apoptotic genes and pathways,
respectively, but it can decrease neuroinflammation and free radicals (Scott,
Zhang et al. 2012). It is also known that estrogen increases cognitive abilities
which is demonstrated by estrogen’s ability to affect many systems in the brain
such as: dopaminergic, cholinergic, serotonergic, and noradrenergic (Pinkerton
and Henderson 2005). This is important in neurodegeneration as
neurotransmitters are a way of communication in the brain. The hippocampus
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uses neurotransmitters to signal long-term potentiation, LTP, needed for
memory. If there is a decrease in estrogen, causing a decrease in
neurotransmitter the hippocampus will have fewer LTP, which affects memory.
Interestingly, the Cache County study demonstrates that post menopausal
women have a decreased memory, which strongly correlates with the decrease
in estrogen leading to fewer LTP (Zandi, Carlson et al. 2002). Specifically in AD,
there is also a sex specific irregular phosphorylation of Tau in the hypothalamus
in 90% of men that occurs in less than 10% of women (Barnes, Wilson et al.
2005). Tau is a microtubule-associated protein that binds microtubules and
initiates anteretrograde transport in the axon by promoting microtubule assembly
that aids in transport of neurotransmitters and receptors from the cell body to the
synapse in neurons (Lashuel, Hartley et al. 2002; Bossy-Wetzel,
Schwarzenbacher et al. 2004). The hyperphosphorylation of Tau leads to the
destabilization of microtubules and the disruption of axonal transport. The
synapse will not receive adequate nutrients and the neuron will die. The damage
in AD occurs mostly in the hippocampus and cortex, which are involved in
memory and higher cognitive processes (Bossy-Wetzel, Schwarzenbacher et al.
2004; Ross and Poirier 2004).
In rodent models of disease, the concentration of estrogen administered
plays a role in the mechanism of how estrogen is protective. Physiological
concentrations of E2 are believed to work through typical steroid hormone
receptor signaling, while pharmacological concentrations have more of an
oxidative effect. Physiological concentrations of E2 mimic blood concentrations
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seen during the reproductive cycle or during pregnancy in women and early life in
men. Pharmacological concentrations are generally 10-10,000 fold higher than
blood concentration levels (Wise, Dubal et al. 2001). In females, physiological
concentrations of E2 vary depending on the phase of the reproductive cycle. In
adult premenopausal humans, circulating levels of estrogen range from 15 - 350
pg/mL, while post-menopausal women have a decrease in E2 to less than 10
pg/ml. Interestingly adult men only have an average circulating level of 10 - 40
pg/ml. In rats, females range from 100 pg/ml in estrous to 400 pg/ml in
proestrous (Shors 2005). Silastic capsules can be used in ovariectomized
female rats to maintain a constant level of E2 and avoid changes in circulating
levels. It is difficult to compare circulating levels of E2 to concentrations applied
in vitro because of the lack of a linear relationship with specific brain region E2
concentrations and the concentration of circulating E2 (Konkle and McCarthy
2011). In vitro studies typically use 0.1 to 100 nM concentrations of E2 in media
(Wise, Dubal et al. 2001). If you start out at 100 pg/ml (~estrous phase
concentrations in rats), you end up 0.3671 nM.

Estrogen and Stroke
Stroke is the third leading cause of death in the U.S. (Lloyd-Jones, Adams
et al. 2009). Ischemic stroke occurs when the tissue is deprived blood flow
resulting in an inadequate supply of oxygen and glucose. This type of stroke
occurs 87% of the time, while the other 13% of strokes are hemorrhagic caused
by a weak blood vessel that ruptures and causes excess bleeding (Roger, Go et
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al. 2012). Stroke can be classified as focal, which is confined to a specific region
of the brain, or global, which involves wide areas of brain tissue.
Rodent models have been developed to mimic the most common type of
ischemic type of stroke in humans. Permanent MCAO is a well-established
model of focal ischemic stroke in rodents. In this model, there is a significant
reduction in cerebral blood flow to the striatum and overlaying cortex (Dubal,
Kashon et al. 1998). This decrease in blood supply leads to necrotic cell death in
the striatum followed by apoptotic cell death in the overlaying cortex (Liu, Smith
et al. 1999). Following MCAO, gonadectomized females (Simpkins, Rajakumar
et al. 1997; Dubal, Kashon et al. 1998; Toung, Traystman et al. 1998; Rusa,
Alkayed et al. 1999; Dubal and Wise 2001) and males (Toung, Traystman et al.
1998; Uchida, Palmateer et al. 2009) have a much larger MCAO-induced injury
than animals with higher circulating estrogen concentrations. Pre-treatment with
even low doses of E2 is sufficient to exert dramatic protection in the brains of
both female (Dubal, Kashon et al. 1998; Dubal and Wise 2001) and male rats
(Toung, Traystman et al. 1998). Estrogen receptors (ER) have been shown to be
important for neuroprotection by estrogen. Generalized pharmacologic blockade
of ER exacerbates ischemic injury in mice (Sawada, Alkayed et al. 2000) and
blocks estrogen-induced neuroprotection in cultured neurons (Singer, FigueroaMasot et al. 1999; Wilson, Dubal et al. 2000) and in cortical explant cultures
(Wilson, Dubal et al. 2000). Studies using ER! knockout females demonstrate
that neuroprotection by E2 following ischemia is dependent on the presence of
ER! in the cortex (Dubal, Zhu et al. 2001), and that ER" alone is not sufficient for
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neuroprotection in females. In male ER! knockout mice, the absence of ER! did
not increase the ischemia-induced damage, but these males were not given
estradiol (Sampei, Goto et al. 2000). In both male and female rodents, ER! is
only transiently expressed in the cortex during neonatal development and then is
virtually absent in the adult (Miranda and Toran-Allerand 1992; Prewitt and
Wilson 2007). 24 hours after MCAO, however, ER! mRNA and protein are
increased in the cortex of female rats and mice (Dubal, Shughrue et al. 1999;
Dubal, Rau et al. 2006). In OVX females, the increase in ER! mRNA occurs in
both oil and E2-treated groups, but is seen earlier after injury with E2 (Dubal,
Rau et al. 2006). These data suggest that in females, the ischemia-induced
increase in ER! in the cortex is necessary for the neuroprotective effects of E2.
In males, the injury-induced regulation of ER! and the mechanisms of E2 action
are still largely unknown.

Injury Models and Cortical Explants
E2 has been shown to be protective in other models of injury. For
example, E2 reduces cell death in cortical and hippocampal neurons along with
cell line exposed to multiple types of injuries reviewed in (McCullough, Koerner et
al. 2009; Herson and Hurn 2010). (Herson, Koerner et al. 2009; McCullough,
Koerner et al. 2009; Liu, Kelley et al. 2010). These studies are predominately
done in cell lines or primary cultures where only one cell type is present. We are
specifically interested in the cortex, because it is a region of the brain that can be
protected with estrogen treatment following stroke. Slices of the cortex can be
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grown in culture where a heterogeneous population of neurons and glia cells can
continue to cross talk as they did in the intact brain. In this model, E2 has also
shown to be protective by reducing cell death in a chemical induced ischemic
injury (Wilson, Dubal et al. 2000; Wilson, Liu et al. 2002). 2DG/KCN blocks
glycolysis and oxidative phosphorylation, which are the two main areas of
disruption when the brain experiences ischemia. By maintaining the synaptic
connections of the whole brain slice, the heterogeneous population of neurons
and glia can add insight to how E2 mediates protection in the cortex.
Cortical explants are taken from PND 3 or 4 rat pups because it is
essential to isolate the explant while this part of the brain is still developing.
Donor pups must be younger than PND7 do ensure viability (Staal, Alexander et
al. 2011). If the explants were taken from a donor animal older than PND 7 they
are not as likely to thrive outside input from other regions of the brain possible
due to the tissue requiring more aerobic-base synthesis, such as oxygen and
ATP from outside sources, for metabolism (Fuller and Dailey 2007).

Healthy

explants are transparent with smooth edges while overfed explants become
opaque and underfed explants thin to the point that they are undetectable (Fuller
and Dailey 2007).

Summary
To investigate the multi-faceted cellular pathways that are involved in cell
death and neuroprotection, a simplified model is needed to isolate specific
mechanisms on how sex differences occur in ischemia. My dissertation will
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investigate sex differences at two time-periods. First, I will examine changes in
sex steroid hormone receptor mRNA expression across time in culture of female
and male cortical explants separately. Then, I will not only examine changes in
sex steroid hormone receptor mRNA expression following injury but also sex
differences in cell death and E2 mediated protection.
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CHAPTER 2
STEROID HORMONE RECEPTOR EXPRESSION DURING EARLY
POSTNATAL DEVELOPMENT IN THE RAT CORTEX IN VIVO AND IN VITRO

Introduction

Sex steroid hormones elicit numerous actions in the brain during
development. These hormones can act through specific steroid hormone
receptors, such as estrogen receptor alpha (ER!), estrogen receptor beta (ER")
and androgen receptor (AR). To understand the many actions of steroid
hormones it is important to examine the expression and distribution of their
receptors. Expression of these receptors in the brain changes across an
animal’s lifetime. Specifically, during early postnatal development in the mouse,
ER! mRNA expression is high in the cortex then decreases where it remains low
in the uninjured adult cortex (Prewitt and Wilson 2007). Interestingly, ER!
expression increases following injury in the adult cortex (Wilson, Westberry et al.
2008). Another example of the dynamic nature of steroid hormone receptor
expression is ER", which increases across early postnatal development and
decreases with aging (Wilson, Rosewell et al. 2002; Westberry, Trout et al.
2011). AR expression also changes by increasing across early postnatal
development in the cortex (Nunez, Huppenbauer et al. 2003) and in the adult
cortex depending on the different phases of the estrus cycle (Feng, Weijdegard
et al. 2010). Little is known about changes in AR with age or following injury. By
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understanding the regulation and expression patterns of these steroid hormone
receptors during early postnatal development we can potentially understand how
they are regulated at other times during an animal’s lifetime, i.e. following a brain
injury. In fact, one theory is that the brain reverts back to its developmental state
following injury to aid in repair (Emery, Royo et al. 2003).
The experiments described in this chapter were designed to accomplish
two goals: First, to test the hypothesis that sex steroid hormone receptor
expression was regulated similarly during postnatal development in the rat cortex
that was seen in previously published mouse studies. Specifically, we predicted
that ER! mRNA expression would decrease and ER" and AR mRNA expression
would increase across early postnatal development. The second goal was to test
the hypothesis that sex steroid hormone receptor mRNA expression also
changed across time in rat cortical explants. I also wanted to test the hypothesis
that E2 pretreatment would alter steroid hormone receptor expression in rat
cortical explants. Specifically, since E2 alters steroid hormone receptor
expression in vivo by positive and negative feedback, E2 would alter expression
of steroid hormone receptors across time in culture, in vitro.
The cortex is a complex brain region with many changes occurring
throughout development and following injury. One way to simplify how the cortex
is studied and focus on its changes is to isolate it away from other regions of the
brain and maintain it in culture. In fact, previous studies from our lab have used
this model to study injury. These initial studies were done in rat cortical explants
and showed that 17"-estradiol (E2) was protective following a chemically induced
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ischemic injury (Wilson, Dubal et al. 2000; Wilson, Liu et al. 2002). One limitation
from those studies was that the cortical explants had combined sections from
both male and female rat pups. With our current knowledge of sex differences in
cell death and in response to injury, we felt it was essential to repeat those
studies separating cortical explants from female and male pups. Another
limitation of those studies was that although they did explore E2 and
neuroprotection using a variety of concentrations of E2 (0.1-100nM), they did not
evaluate how E2 altered expression of steroid hormone receptors from the time
that the cortical explants were plated. Here, we addressed these limitations by
separating the pups based on sex before cortical explants were taken and by
measuring sex steroid hormone receptor mRNA expression in rat cortical
explants at several time-points after plating (1, 7, 15 and 22 days in culture, DIC)
with and without the presence of E2.
More recently our lab was interested in the expression of steroid hormone
receptors in the mouse cortex and in explants cultures taken from mice (Prewitt
and Wilson 2007; Westberry, Prewitt et al. 2008). Our interest in mice was due
to the possibility of utilizing knockout strains to learn E2 mediated
neuroprotection mechanisms. A recent study from our lab compared expression
patterns of ER! and ER" across development in vivo and in vitro in mice (Prewitt
and Wilson 2007). ER! mRNA and protein expression decreased and ER"
mRNA and protein expression increased across early postnatal development in
the cortex and across time in mice cortical explants (Prewitt and Wilson 2007).
Interestingly, no sex differences in mRNA or protein expression were reported in
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the cortex or in cortical explants taken from mice (Prewitt and Wilson 2007).
Although this study separated the mice pups based on sex before explant
dissections, the influence of E2 on the expression of steroid hormone receptors
across time in culture was not evaluated. It is important to know if E2
pretreatment caused any changes in steroid hormone expression even before
the injury was induced. These studies provided a solid rationale to look at both
mice and rat cortical explants. Unfortunately due to some initial technical
difficulties with mice, including: small litter size and female to male ratios in litters,
I decided to exclusively use rat cortical explants.
In the following studies, I tested the hypothesis that sex steroid hormone
receptor (ER!, ER" and AR) expression was regulated similarly during postnatal
development in the rat cortex as the mouse cortex. I also wanted to test the
hypothesis that ER!, ER" and AR mRNA expression also changed across time
in culture in rat cortical explants. To accomplish my goals for this chapter, I
isolated mRNA from the cortex and from cortical explants of female and male
rats and measured ER!, ER" and AR mRNA expression. By understanding the
regulation and expression patterns of these steroid hormone receptors during
early postnatal development, we can potentially understand how they are
regulated at other times during an animal’s life, i.e. following brain injury.
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Methods

Animal Care and Housing
All animals used in these experiments were Sprague Dawley rats.
Pregnant dams were purchased from Harlan Laboratories (Indianapolis, IN) and
maintained in constant temperature conditions on a 12-hour light/dark cycle.
Dams were provided food and water ad libitum. Pups were sexed and taken
from their mother at postnatal day (PND) 3, 4, 10, and 18, with PND 0 as the day
of birth. For the PND 25 time-point, pups were weaned from their mother at PND
22, sexed and placed in separate cages until PND 25. The Animal Care and Use
Committee of the University of Kentucky approved all experimental procedures.

Collection of brain tissue
Animals were killed by rapid decapitation and the brains removed. On ice,
the cortex was dissected from the corpus callosum with care not to include the
piriform cortex, striatum and the hippocampus. The cortex was collected from
Bregma -.36 to -2.64 mm (C 2007). See Figure 2.1. Tissue was collected on ice
and frozen at -80 oC until processing.
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Figure 2.1. Diagram of the cortical region used in experiments. The cortex
was collected from Bregma -0.36 to -2.64 mm. Regions of cortex that we
collected included primary and secondary motor cortex along with some
somatosensory cortex. The motor cortex controls voluntary movements by
planning, control and execution of the movements. Neuronal axons from the
motor cortex synapse onto motorneurons in the spinal cord, which have axons
that synapse to a muscle.
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Collection of cortical explants
Pups were taken at postnatal day 3 (PND3) with PND 0 considered day of
birth. Pups were sexed and rapidly decapitated. As previously described
(Wilson, Rosewell et al. 2002), brains were isolated and sectioned at 300 !m on
a vibratome. Cortical pieces were dissected form Bregma -.36 to -2.64 mm (C
2007). Regions of cortex included primary and secondary motor cortex along
with somatosensory cortex (see Figure 2.1 for representative brain sections and
Figure 2.2 for diagram of explant procedure). The cortex was dissected away
from the corpus callosum with care not to include the piriform cortex, striatum
and the hippocampus. Approximately 8-10 slices were harvested per brain. The
explants were sectioned in dissection media containing Gey’s balanced salt
solution (G9779, Sigma-aldrich, Saint Louis, MO), 0.2 M MgCl2 and 37.5%
glucose in Geys BSS and kept in dissection media plus ketamine HCl (Ketaset,
NLS Animal Heath, Pittsburg PA) on ice until the cortex was isolated and
separated into individual hemispheres. Four individual cortices were plated on
Millicell-CM membranes (PICMO3050, Fisher, Hampton, NH) in wells containing
media of 1X Basal Medium Eagle (BME) (B9638, Sigma-aldrich, Saint Louis,
MO), Hanks’ Balanced Salt Solution (HBSS) (14025, Invitrogen), heat-inactivated
horse serum (3H30074.03, Fisher, Hampton, NH), 37.5% glucose in Geys BSS,
glutamax (35050, Invitrogen, Carlsbad, CA), and penicillin/streptomycin (15140,
Invitrogen, Carlsbad, CA). The media also contained either 17 !-estradiol (E2) (1
nM in 0.01% EtOH) (1,3,5(10)-Estratrien-3,17-!-Diol, 122323, Steraloids, Inc,
Newport, RI) or EtOH (0.01%) vehicle. Media containing E2 or vehicle was
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Brain isolated

300 µm sections cut on
Vibratome

Brain dissected from
Bregma 0.36 to -2.64
!

Cortex dissected away
from the corpus callosum
Explants plated 5-6 per well
on a milli-cell membranes in
a 6 well plate

Figure 2.2. Summary of rat cortical explants protocol. Female and male
PND3 rat pups were decapitated, the brain isolated and sectioned on a
vibratome to 300 um. The cortex was isolated and plated on a milli-cell
membrane inserted into a 6 well plate.
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Explants
Collect in Trizol

Collect in Trizol

Collect in Trizol

Collect in Trizol

Day of Birth
PND 0

3 4

10

18

25

1
DIC

7 DIC

15 DIC

22 DIC

Figure 2.3. Time-line for the collection of cortical tissue and cortical
explants. The above diagram shows a timeline of cortical tissue collection from
day of birth (PND 0) to PND 25. Also diagramed is the timeline of cortical
explants collection from 1 DIC to 22 DIC.
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changed every three days. Explants remained in culture at 34oC with 5% CO2 for
1 to 22 days.

RNA Isolation
Cortical tissue and explants were collected at PND 4 (1 DIC), PND 10 (7
DIC), PND 18 (15 DIC) and PND 25 (22 DIC) (see Figure 2.3 for time-line) to
determine mRNA expression changes across time in culture. To collect RNA,
cortical tissue or at least 3 explants were combined and homogenized in TriZol
(Invitrogen, Carlsbad, CA). RNA was isolated, the resulting pellet was air-dried
and resuspended in RNase-free water (DEPC) (BP561, Fisher). The RNA was
then be incubated at 56°C for 10 minutes and stored at -80 oC until reverse
transcription.

Reverse Transcription
One µg of total RNA was reverse transcribed to produce cDNA. DEPC
H20 was added to bring 1 µg of total RNA for each sample to a final volume of
20µl. 1 µl of Random Primers (58875, Invitrogen, Carlsbad, CA) and 1 µl of 10
mM dNTP’s (U1515, Promega, Madison, WI) were added to each reaction. The
samples were incubated at 65 oC for 5 minutes. 8 µl of Master Mix containing 4
µl of 5x first strand buffer (Y02321, Invitrogen, Carlsbad, CA), 2 µl of 0.1 M DTT
(Y00147, Invitrogen, Carlsbad, CA), 1 µl of RNasin (N211B, Promega, Madison,
WI) and 1 µl of Superscript II RT (100004925, Invitrogen, Carlsbad, CA) were
added to each reaction. The samples were incubated at room temperature for 10
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minutes, 42oC for 50 minutes, then 70 oC for 15 minutes. The cDNA was stored
at -80 oC until quantitative real time PCR.

Quantitative Real Time PCR
For real time PCR, each reaction contained 10.125 µl DEPC H20, 12.5 µl
of Brilliant II SYBR@Green QPCR Master Mix (Agilent Technologies, catalog
#600828, Santa Clara, CA), 0.375 µl of Reference Dye (diluted 1:500) (Agilent
Technologies, Santa Clara, CA), 0.5 µl of forward primer, 0.5 µl of reverse primer
and 1µg of appropriate cDNA. Primer specific concentrations were previously
optimized for each gene and result in a single PCR product with no primer-dimer
formation. Each 96 well plate contained a non-template control and each sample
was run in triplicate. The cycling parameters were as follows: 1 cycle at 95°C for
10 minutes, 40 cycles of 95°C for 30 seconds, annealing temperature for 1
minute, 72°C for 30 seconds, and 1 cycle of 95°C for 1 minute and 55°C for 30
seconds. The change in threshold cycle (!Ct) for each sample was normalized to
the constitutively expressed housekeeping control gene Histone 3.1 (Wilson and
Handa 1997). The primers used for each gene are shown in Table 1. RNA was
collected from at least 3 wells per condition at each time-point. At least 3
explants per time-point from each condition were visualized and each experiment
was independently repeated 3 times.
For each gene of interest the change in threshold cycle (!Ct) for each
sample was normalized to the constitutively expressed housekeeping control
gene Histone 3.1 (Wilson and Handa 1997). !!Ct were then calculated by
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comparing the data to a earlier reference point, PND 4 or 1 DIC (Livak and
Schmittgen 2001). For example, housekeeping Ct values are subtracted from
ER! Ct values at PND 25 in females. This change in Ct values, !Ct, at PND 25
was compared back to an early time-points PND4 !Ct value creating a !!Ct.
Real time PCR data was analyzed by logarithmically raising the changes in Ct at
the two time-points, 2-!!Ct (Livak and Schmittgen 2001) and graphed as a ratio of
gene of interest to housekeeping gene. Error bars on each graph are standard
error of the mean.
To look at relative levels of mRNA expression and not a fold change
compared back to an earlier time-point, the average housekeeping Ct values for
all corresponding samples of the same sex and time-point were divided by and
individual sample housekeeping Ct value. The ratio of housekeeping Ct values
(average housekeeping Ct value/ sample housekeeping Ct value) was multiplied
by the Ct value for the gene of interest for the same sample.
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Table 2.1. Primer Information. List of primers used for real time PCR.

Gene

GI #

Primer
Location

His
318068040 208-425
3.1
ER
6978814
alpha

!

19912055

ER
beta

6978816 454-715

AR

6978534

27392833

Forward Primer (F)
Reverse Primer (R)
F 5’-GCAAGAGTGCGCCCTCTACTG-3’
R 5’GGCCTCACTTGCCTCCTGCAA-3’
F 5’-GGGCTTCCCCAACACCAT-3’
R 5’-CGTTTCAGGGATTCGCAGAA-3’

Ref
(Wilson and
Handa 1997)
(Takagi,
Shibutani et al.
2005)
(Kuiper, Carlsson
et al. 1997)

F 5’-TTCCCGGCACGACCAGTAACCT-3’
R 5’TCCCTCTTTGCGTTGGACTA-3’
F 5’TGATTGCACCATTGATTGATAAATTTCG-3’
(Bowman 2005)
R 5’GCTTACGAGCTCCCAGAGTCA-3’

35

Table 2.2 List of companies and locations of materials used in methods.

!

Company
Agilent Technologies

Home Office
Santa Clara, CA

Fisher

Hampton, NH

Invitrogen
NLS Animal Heath

Carlsbad, CA
Pittsburg PA

Promega

Madison, WI

Sigma-Aldrich
Steraloids, Inc

Saint Louis, MO
Newport, RI

Tocris

Bristol, United Kingdom
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Statistics
In vivo
For mRNA studies, female and male cortical tissue was collected from at
least 3 different litters at each of the time-points (PND 4, 10, 18 and 25). At least
one female and one male were sampled from each of the 3 litters and at least 6
animals were taken at each time-point. For each gene of interest the change in
threshold cycle (!Ct) for each sample was normalized to the constitutively
expressed housekeeping control gene Histone 3.1 (Wilson and Handa 1997).
!!Ct was then calculated by comparing the !Ct for the time-point (PND) to the
!Ct of PND 4 females. For example, housekeeping Ct values are subtracted
from ER! Ct values at PND 25 in females. This change in Ct values, !Ct, at
PND 25 was compared back to an early time-point PND4 !Ct value creating a
!!Ct. Real time PCR data was analyzed by logarithmically raising the changes
in Ct at the two time-points, 2-!!Ct (Livak and Schmittgen 2001). All data for the in
vivo experiments were analyzed using a two-way Analysis of Variance (ANOVA)
comparing the factors “sex” and “postnatal day (PND).” To determine what
contributes to the main effect of PND or interactions between sex and PND a
Student Neuman-Keuls post-hoc test was performed. Differences were
considered significant at p<0.05.

In vitro
Statistical analyses of the cortical explant data were more elaborate. For
these mRNA studies, 3 litters were used to dissect female and male cortical

!

37

explants. These explants were grown in media containing EtOH or E2 for
various days in culture (1, 7, 15 and 22 DIC). Each time-point included the
collection of at least 3 explants (N=1) per well that was repeated independently at
least 3 times. For example, the 3 females explants grown in EtOH treated media
for 1 DIC was collected for an N of 1. This was repeated at least 3 times with a
new set of litters each time.
For each gene of interest the change in threshold cycle (!Ct) for each
sample was normalized to the constitutively expressed housekeeping control
gene Histone 3.1 (Wilson and Handa 1997). !!Ct were then calculated by
comparing the !Ct for the time-point (PND) to the !Ct of 1 DIC vehicle treated
explants for the corresponding sex. For example, housekeeping Ct values are
subtracted from ER! Ct values from the 22 DIC E2-treated females. This change
in Ct values, !Ct, at 22 DIC was compared back to an early time-point, 1 DIC
vehicle-treated females cortical explants, !Ct value creating a !!Ct. Real time
PCR data was analyzed by logarithmically raising the changes in Ct values at the
two time-points, 2-!!Ct (Livak and Schmittgen 2001).
The effect of treatment across DIC was determined by a two-way ANOVA
comparing the factors “treatment” (EtOH or E2 treated) and “DIC” for female
explants and then for male explants. This allowed us to determine if treatment
had and effect on the mRNA expression or if DIC had and affect on the mRNA
expression in either female or male cortical explants. To determine what
contributes to the DIC effect or interaction between treatment and DIC a Student
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Neuman-Keuls post-hoc test was performed. Differences were considered
significant at p<0.05.

Results
Part 1: Sex steroid hormone receptor expression in the female and male
cortex across postnatal day (in vivo).
Female and male rats were killed at postnatal day (PND) 4, 10, 18, and
25. Brains were removed and RNA was collected from the cortex. RNA was
converted to cDNA and used for real time PCR to examine ER alpha (ER!), ER
beta (ER") or androgen receptor (AR) mRNA expression. For each time point, at
least 6 animals from different litters were included. Samples were run in triplicate
and compared to the housekeeping gene Histone 3.1. All data were compared
back to female PND 4.

Are there sex differences in sex steroid hormone receptor mRNA
expression across development?
ER!
ER! mRNA significantly decreased across early postnatal development.
Interestingly, there was not a sex difference in ER! mRNA expression (Figure
2.4). Sex differences across postnatal day were evaluated by a two-way analysis
of variance (ANOVA) comparing the factors “sex” (female and male) and
“postnatal day” (PND 4, 10, 18 and 25). Overall there was a significant main
effect of postnatal day (p= 0.0015, F= 5.693, df= 3, 72), but no main effect of sex
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and no interaction (Figure 2.4). To determine which days were different a
Student Neuman-Keuls post-hoc test was performed and revealed that ER!
mRNA expression was significantly decreased at both PND 18 and 25 compared
to PND 10 and to PND 4 (p< 0.05). Overall, ER! mRNA expression decreased
across postnatal development regardless of sex.
To look at relative levels of mRNA expression, not a change compared
back to PND 4, the ratio of housekeeping Ct values (average specific PND
housekeeping Ct value/ sample housekeeping Ct value) was multiplied by the Ct
value for the gene of interest for the same sample, Table 2.3. I have included
average Ct values for ER! and His 3.1 for female and males at each time-point,
Table 2.4. This table highlights ER! Ct values normalized to average histones
that can be compared across PND. The graphs, Figure 2.4, have Ct values
logarithmically expressed relative to PND 4; however, the chart has raw ER! Ct
values normalized to average histone Ct values that can be compared across
PND. The chart Ct values show a substantial change in Ct values that are less
than 30. For real time PCR, the lower the Ct values the more mRNA and
changes that are less than 30 are considered “real.” Ct values greater than 30
occur during the plateau phase of the logarithmic PCR cycle where there is an
increase chance of error (reviewed in (Wong and Medrano 2005)). The chart Ct
values correspond to the logarithmic change seen in the graphs. For the female
and male cortex, ER! Ct values showed a decrease across PND.
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ER Alpha mRNA Expression
in the Cortex

Relative levels of ER alpha mRNA

6

Female
5

Male

4

a

3

*

2

a
*

1
0
PND4

PND10

PND18

PND25

Postnatal Day
Figure 2.4. ER! mRNA expression in the rat cortex across early postnatal
development. ER! mRNA decreased across early postnatal development in
both female and male cortex. There were no sex differences in ER! mRNA
expression at any of the postnatal days. The graph shows ER! relative to the
housekeeping gene histone 3.1. Ct values from each postnatal day were
compared to female PND 4. Asterisks on the graph indicate significant
differences from PND 4, p< 0.05. The letter “a” on the graph indicates significant
differences from PND 10, p< 0.05.
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Table 2.3 Example calculations to look at relative levels of mRNA
expression. The ratio of housekeeping Ct values (average housekeeping Ct
value/ sample housekeeping Ct value) was multiplied by the Ct value for the
gene of interest for the same sample.
PND

Gender

Histone Ct

ER alpha Ct

PND4

F

PND4

F

PND4

F

PND4

F

15.42
15.41
14.46
14.64
19.51
17.69
17.02
14.75
14.24
14.06

25.62
25.71
25.19
25.21
25.61
25.59
25.72
22.96
22.93
23.11

PND4

F

19.17

23.87

19.16

23.95

19.04

23.79

18.71

23.33

18.56

23.46

18.67

23.55

17.41

23.37

PND4

PND4

PND4

PND4

PND4

PND4

PND4

PND4

PND4

F

F

F

F

F

F

F

F

F

Average

!

16.83

23.8

14.92

22.55

15.07

23.04

15.1

23.45

16.43

23.13

16.34

25.19

16.52

24.16

16.15

21.59

16.27

21.45

15.88

21.4

16.42

20.97

16.27

21.06

16.62

21.06

17.67

23.03

18.02

23.01

18.16

23.11

16.44

21.06

16.64

21.25

16.72

21.46

ER alpha * (avg histone/histone)
27.64
27.75
28.98
28.65
21.84
24.06
25.14
25.89
26.79
27.34
20.71
20.79
20.79
20.74
21.03
20.98
22.33
23.91
25.01
24.45
23.82
23.52
25.14
25.43
25.83
23.42
25.64
24.33
22.24
21.93
22.42
21.24
21.53
21.08
21.68
21.24
21.17
21.31
21.24
21.35

16.64

23.34

23.51

16.07

23.1

15.49

23.29

16.61

24.41

16.84

24.11
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Table 2.4 Average real time PCR Ct values from housekeeping gene histone
3.1 and ER! on postnatal day 4, 10, 18 and 25. Bolded box on Table A
(females) and Table B (males) indicates ER! Ct values normalized to average
histones for each postnatal day. These ER! and histone Ct values show a
normalized value for ER! throughout postnatal day. These values allow us to
look at the change in ER! across postnatal day. The normalized Ct value
indicates the relative amount of mRNA in the sample taking into consideration
amount of total mRNA. Table A (female) and Table B (male) correspond to the
overall decrease in ER! mRNA throughout early postnatal development. Note:
higher Ct values indicate a lower expression level of mRNA by representing a
greater number of PCR cycles to reach a maximum.
A.
Average Ct value
Sex

PND

Female

4
10
18
25

Histone
16.64
17.75
17.71
20.8

ER alpha
23.34
23.72
26.37
28.03

Ct value
normalized to
average histone
23.51
23.31
26.65
28.33

B.
Average Ct value

!

Sex

PND

Male

4
10
18
25

Histone
16.77
17.28
17.92
20.2
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ER alpha
23.46
23.8
27.56
27.96

Ct value
normalized to
average histone
23.64
23.95
27.67
28.1

ER!
ER! mRNA significantly increased across early postnatal development.
Interestingly, there was not a sex difference in ER! mRNA expression (Figure
2.5). Sex differences across postnatal day were evaluated by a two-way analysis
of variance (ANOVA) comparing the factors “sex” (female and male) and
“postnatal day” (PND 4, 10, 18 and 25). Overall there was a significant main
effect of postnatal day (p< 0.0001, F= 47.289, df= 3, 67), but no main effect of
sex and no interaction. To determine which days are different a Student
Neuman-Keuls post-hoc test was performed and revealed that ER! mRNA
expression was significantly increased at PND 25 compared to PND 4, 10 and 18
(p< 0.05), Figure 2.5. Overall, ER! mRNA expression increased across
postnatal development regardless of sex.
To look at relative levels of mRNA expression, not a change compared
back to PND 4, the ratio of housekeeping Ct values (average specific PND
housekeeping Ct value/ sample housekeeping Ct value) was multiplied by the Ct
value for the gene of interest for the same sample, Table 2.5. I have included
average Ct values for ER! and His 3.1 for female and males at each time-point,
Table 2.5. This chart highlights ER! Ct values normalized to average histones
that can be compared across PND. For the female and male cortex, ER! Ct
values showed that there was an increase in mRNA expression across PND.
The graphs, Figure 2.5, have Ct values logarithmically expressed relative to PND
4; however, the table has raw ER! Ct values normalized to average histone Ct
values that can be compared across PND. The chart Ct values show a
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substantial change in Ct values that are less than 30. For real time PCR, the
lower the Ct values the more mRNA and changes that are less than 30 are
considered “real.” Ct values greater than 30 occur during the plateau phase of
the logarithmic PCR cycle where there is an increase chance of error (reviewed
in (Wong and Medrano 2005)). The chart Ct values correspond to the
logarithmic change seen in the graphs. For the female and male cortex, ER! Ct
values showed an increase across PND.
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Relative levels of ER Beta mRNA
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ER Beta mRNA Expression
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Figure 2.5. ER! mRNA expression in the cortex across postnatal
development. ER! mRNA increased across early postnatal development in
both female and male cortex. There was no sex difference in ER! mRNA
expression at any of the postnatal days. The graph shows ER! relative to the
housekeeping gene histone 3.1. CT values from each postnatal day were
compared to female PND 4. Asterisks on the graph indicate significant increase
in ER! mRNA at PND 25 from PND 4,10 and 18, p< 0.05.
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Table 2.5. Average real time PCR Ct values from housekeeping gene
histone 3.1 and ER! on postnatal day 4, 10, 18 and 25. Bolded box on Table
A (females) and Table B (males) indicates ER! Ct values normalized to average
histones for each postnatal day. These raw numbers show a normalized value
for ER! throughout postnatal day. The normalized Ct value indicates the relative
amount of mRNA in the sample taking into consideration amount of total mRNA.
Table A (female) and Table B (male) correspond to the overall increase in ER!
mRNA throughout early postnatal development (Figure 2.5). Note: higher Ct
values indicate a lower expression level of mRNA by representing a greater
number of PCR cycles to reach a maximum.

A.
Average Ct value
Sex

PND

Female

4
10
18
25

Histone
16.64
17.58
17.71
19.89

ER beta
29.55
28.76
27.56
26.27

Ct value
normalized to
average histone
27.33
28.44
27.75
26.27

B.

Average Ct value

!

Sex

PND

Male

4
10
18
25

Histone
16.77
17.28
17.76
19.46

ER beta
30.05
27.95
28.77
25.8
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Ct value
normalized to
average histone
27.56
28.1
28.96
25.8

AR
AR mRNA significantly increased across early postnatal development.
Interestingly, there was no sex difference in AR mRNA expression (Figure 2.6).
Sex differences across postnatal day were evaluated by a two-way analysis of
variance (ANOVA) comparing the factors “sex” (female and male) and “postnatal
day” (PND 4, 10, 18 and 25). Overall there was a significant main effect of
postnatal day (p< 0.0001, F= 16.764, df= 3, 66), but no main effect of sex and no
interaction. To determine which days were different a Student Neuman-Keuls
post-hoc test was performed and revealed that AR mRNA expression was
significantly increased at PND 18 and 25 compared to PND 4 and 10 and
significantly increased at PND 25 compared to PND 18 (p< 0.05), Figure 2.6.
Overall, AR mRNA expression increased across postnatal development
regardless of sex.
To look at relative levels of mRNA expression, not a change compared
back to PND 4, the ratio of housekeeping Ct values (average specific PND
housekeeping Ct value/ sample housekeeping Ct value) was multiplied by the Ct
value for the gene of interest for the same sample, Table 2.6. I have included
average Ct values for AR and His 3.1 for female and males at each time-point,
Table 2.6. This chart highlights AR Ct values normalized to average histones
that can be compared across PND. For the female and male cortex, AR Ct
values showed that there was an increase in mRNA expression across PND.
The graphs, Figure 2.6, have Ct values logarithmically expressed relative to PND
4; however, the table has raw AR Ct values normalized to average histone Ct
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values that can be compared across PND. The chart Ct values show a
substantial change in Ct values that are less than 30. For real time PCR, the
lower the Ct values the more mRNA and changes that are less than 30 are
considered “real.” Ct values greater than 30 occur during the plateau phase of
the logarithmic PCR cycle where there is an increase chance of error (reviewed
in (Wong and Medrano 2005)). The chart Ct values correspond to the
logarithmic change seen in the graphs. For the female and male cortex, AR Ct
values showed an increase across PND.
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Relative levels of AR mRNA

350

a

200

*

*

300
250

b
a

AR mRNA Expression
in the Cortex

Female
Male

150
100
50
0
PND4

PND10

PND18

PND25

Postnatal Day
Figure 2.6. AR mRNA expressions in the cortex across postnatal
development. AR mRNA increased across early postnatal development in
female and male in the cortex. There was no sex difference in AR mRNA
expression at any of the postnatal days. The graph shows AR expression relative
to the housekeeping gene histone 3.1. Ct values from each postnatal day were
compared to female PND 4. Asterisk on the graph indicate significant increases
from PND 4, p<0.05. The letter “a” on the graph indicates significant increases
from PND 10, p< 0.05. The letter “b” on the graph indicates significant increases
from PND 18, p< 0.05.
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Table 2.6 Average real time PCR Ct values from housekeeping gene histone
3.1 and AR on postnatal day 4, 10, 18 and 25. Bolded box on table A
(females) and table B (males) indicates AR Ct values normalized to average
histones for each postnatal day. These raw numbers allow you to evaluate a
normalized value for AR throughout postnatal day. The normalized Ct value
indicates the relative amount of mRNA in the sample taking into consideration
amount of total mRNA. Table A (female) and Table B (male) correspond to the
overall increase in AR mRNA throughout early postnatal development (Figure
2.6). Note: higher Ct values indicate a lower expression level of mRNA by
representing a greater number of PCR cycles to reach a maximum.

A.
Average Ct value
Sex

PND

Histone

AR

Female

4
10
18
25

16.66
17.58
17.71
19.89

30.3
25.55
24.08
26.27

Ct value
normalize to
average histone
28.59
25.58
24.28
26.27

B.
Average Ct value

!

Sex

PND

Histone

AR

Male

4
10
18
25

16.77
17.15
17.92
19.46

30.08
26.92
25.67
25.36
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Ct value
normalize to
average histone
27.65
25.85
25.65
25.37

We found that the expression patterns of sex steroid hormone receptors
were the same in the rat cortex as in the mouse cortex across development. My
hypothesis that ER! decreased and ER" and AR increased in mRNA expression
across early postnatal development in the rat cortex was confirmed. Additionally,
there was not a sex difference in relative level or pattern of expression in ER!,
ER" or AR mRNA across development.
Part 2: Steroid hormone receptor mRNA expression in female and male rat
cortical explants across time in culture (in vitro).
Cortical explants were isolated from postnatal day 3 (PND 3) rat pups and
grown for 1 to 22 days in culture with media containing either 17"-estradiol (E2)
(1 nM in 0.01% EtOH) or EtOH (0.01%) vehicle. Explants were collected for
RNA at 1, 7, 15 and 22 days in culture (DIC). Each time-point included the
collection of at least 3 explants (N=1) per well that was repeated independently at
least 3 times. For example, 3 females explants were grown in EtOH treated
media for 1 DIC were collected and combined as an N of 1. This was repeated
at least 3 times with a new set of litters each time. RNA was isolated from the
explants and converted to cDNA where it was used for real time PCR to examine
ER alpha (ER!), ER beta (ER") or androgen receptor (AR) mRNA expression.
Samples were run in triplicate and compared to the housekeeping gene Histone
3.1. All data were compared back to 1 DIC for each vehicle-treated sex.
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ER!
Does E2 influence ER! mRNA expression in rat cortical explants across
time in culture?
To answer this question, we analyzed mRNA expression by statistically
comparing treatment (EtOH and E2) and days in culture (DIC) separately for
female cortical explants and male cortical explants. ER! mRNA expression
significantly decreased in female and male cortical explants that were EtOH and
E2 treated.
In female cortical explants, ER! mRNA expression decreased in cortical
explants across time in culture (1 to 22 DIC), but treatment in the feed media was
not a factor (Figure 2.7). For the female explants grown in media containing
vehicle and E2, a two-way ANOVA comparing the factors “treatment” and “DIC”
revealed a significant main effect of DIC (p= 0.002, F= 7.839, df= 3, 65), but no
main effect of treatment and no interaction. To determine which DIC were
different a Student Neuman-Keuls post-hoc test was performed and revealed that
ER! mRNA expression was significantly decreased at 7, 15 and 22 DIC
compared to 1 DIC (p< 0.05). Overall, these data demonstrate that ER! mRNA
expression decreased in female rat cortical explants regardless if E2 was present
in the feed media.
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ER Alpha mRNA Expression
In Female Cortical Explants

Relative levels of ER alpha mRNA
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Figure 2.7. ER! mRNA expression in female cortical explants grown in
culture. ER! mRNA decreased across time in culture in vehicle and E2-treated
female cortical explants. There was no treatment difference in ER! mRNA
expression at any of the postnatal days. The graph above shows ER! relative to
the housekeeping gene histone 3.1. Ct values from each postnatal day are
compared to 1DIC vehicle-treated females explants. Asterisks on the graph
indicate significant decreases at 7, 15, and 22 DIC, p< 0.05.
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In male cortical explants, ER! mRNA expression decreased across time
in culture (1 to 22 DIC) and E2 influenced the expression. This is different from
what we see in female cortical explants (Figure 2.7), because female cortical
explants did not have an effect of treatment. For the male explants grown in
media containing vehicle and E2, a two-way ANOVA comparing the factors
“treatment” and “DIC” revealed a significant main effect of DIC (p=0.0345,
F=3.091, df= 3, 54) and of treatment (p=0.0190, F= 5.852, df= 1, 54), but no
interaction. Vehicle (EtOH)-treated male cortical explants had an increased ER!
mRNA expression compared to E2-treated male cortical explants. To determine
which DIC were different a Student Newman-Keuls post-hoc test was performed
and revealed that 1 DIC was significantly greater than 22 DIC when both E2 and
vehicle were collectively compared against 1 DIC (p< 0.05), indicated by an
asterisk in Figure 2.8. Overall, male cortical explants had a decrease in ER!
mRNA expression and E2-treatment significantly lowered this expression.
To look at relative levels of mRNA expression, not a change compared
back to vehicle-treated explants grown for 1 DIC, the ratio of housekeeping Ct
values (average specific PND housekeeping Ct value/ sample housekeeping Ct
value) was multiplied by the Ct value for the gene of interest for the same
sample. The average Ct values for ER! and His 3.1 are located in Table 2.7 for
vehicle and E2 treated female and male cortical explants at each time-point.
This table highlights ER! Ct values normalized to average histones that can be
compared across PND. For the female and male cortical explants, ER! Ct
values decreased across PND. ER! Ct value normalized to average histone in
!
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both female and male were not significantly different from each other, but they
did change significantly over time, represented in Figures 2.7-2.8.
To look at relative levels of mRNA expression, not a change compared
back to 1 DIC, the ratio of housekeeping Ct values (average specific 1 DIC
housekeeping Ct value/ sample housekeeping Ct value) was multiplied by the Ct
value for the gene of interest for the same sample, Table 2.7. I have included
average Ct values for ER! and His 3.1 for female and males at each time-point,
Table 2.7. This chart highlights ER! Ct values normalized to average histones
that can be compared across PND. For the female and male cortex, ER! Ct
values showed that there was a decrease in mRNA expression across time in
culture. The graphs, Figure 2.7-2.8, have Ct values logarithmically expressed
relative to PND 4; however, the table has raw ER! Ct values normalized to
average histone Ct values that can be compared across 1 DIC. The chart Ct
values show a substantial change in Ct values that are less than 30. For real
time PCR, the lower the Ct values the more mRNA and changes that are less
than 30 are considered “real.” Ct values greater than 30 occur during the plateau
phase of the logarithmic PCR cycle where there is an increase chance of error
(reviewed in (Wong and Medrano 2005)). The chart Ct values correspond to the
logarithmic change seen in the graphs. For the female and male cortex, ER! Ct
values showed a decrease across DIC.
As demonstrated in mice cortical explants, ER! mRNA expression
decreased in the cortical explants across time in culture in both female and male
rat cortical explants. These data suggest that the expression patterns of steroid
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hormone receptors also change in rat cortical explants, which confirms our
hypothesis that ER! mRNA expression will decrease across time in culture.
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ER Alpha mRNA Expression
In Male Cortical Explants

Relative levels of ER alpha mRNA
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Figure 2.8. ER! mRNA expression in male cortical explants. ER! mRNA
decreased across time in culture in vehicle and E2-treated male cortical explants.
ER! mRNA expression at 1 DIC was significantly greater than at 22 DIC for both
E2 and vehicle-treated explants, indicated by an asterisk, p< 0.05. E2 treatment
significantly lowered ER! mRNA expression compared to vehicle, not indicated
on the graph.
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Table 2.7 Average real time PCR Ct values from housekeeping gene histone
3.1 and ER! in cortical explants grown for 1, 7, 15 and 22 days in culture
(DIC). Bolded box on table A and B (females) and table C and D (males)
indicates ER! Ct values normalized to average histones for each postnatal day.
Note: higher Ct values indicate a lower expression level of mRNA by
representing a greater number of PCR cycles to reach a maximum.
A
Sex

DIC

Female

1
7
15
22

EtOH Treated Average Ct Value
Histone
ER alpha
18.94
26.34
18.54
27.33
20.19
27.61
19.69
28.84

Ct value normalize to
average histone

E2 Treated Average Ct Value
Histone
ER alpha
19.46
26.23
18.45
28.16
19.68
27.37
19.45
29.85

Ct value normalize to
average histone

EtOH Treated Average Ct Value
Histone
ER alpha
19.85
26.21
18.78
26.72
19.77
26.58
19.84
27.33

Ct value normalize to
average histone

25.77
26.37
27.63
28.58

B
Sex

DIC

Female

1
7
15
22

26.34
26.83
27.42
29.87

C
Sex

DIC

Male

1
7
15
22

26.43
25.91
26.19
27.27

D
Sex
Male

!

DIC
1
7
15
22

E2 Treated Average Ct Value
Histone
ER alpha
19.04
26.44
19.72
26.72
19.53
26.72
19.51
28.33
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Ct value normalize to
average histone
26.59
25.59
26.88
28.19

ER!
Does E2 influence ER! mRNA expression in rat cortical explants across
time in culture?
To answer this question, we analyzed mRNA expression by statistically
comparing treatment (EtOH and E2) and days in culture (DIC) separately for
female cortical explants and male cortical explants. ER! mRNA expression
significantly increased in both vehicle and E2-treated female and vehicle and E2treated male cortical explants across time in culture.
In female cortical explants, ER! mRNA expression increased in cortical
explants across time in culture (1 to 22 DIC), but treatment in the feed media is
not a factor. For the female explants grown in media containing vehicle and E2, a
two-way ANOVA comparing the factors “treatment” and “DIC” revealed a
significant main effect of DIC (p= 0.0043, F= 4.815, df= 3, 66), but no main effect
of treatment and no interaction. To determine which DIC were different a
Student Neuman-Keuls post-hoc test was conducted and revealed that ER!
mRNA expression was significantly increased at 15 DIC compared to 1 DIC (p<
0.05) and significantly increased at 15 and 22 DIC compared to 7 DIC (p< 0.05)
(Figure 2.9). These significant differences include data from both vehicle and E2
treated female cortical explants because there was not an effect of treatment.
Overall, these data demonstrate that ER! mRNA expression increased across
time in culture in female rat cortical explants regardless if E2 was present in the
feed media.
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Relative levels of ER Beta mRNA

ER Beta mRNA Expression
In Female Cortical Explants
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Figure 2.9. ER! mRNA expression in female cortical explants. ER! mRNA
increased across time in culture in vehicle and estrogen-treated cortical explants.
The graph above shows ER! relative to the housekeeping gene histone 3.1. Ct
values from each postnatal day are compared to 1 DIC for each media treatment.
Significant increases at 15 DIC compared to 1 DIC are indicated by asterisks on
the graph and significant increases at 15 and 22 DIC compared to 7 DIC are
indicated by an “a”, p< 0.05.
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In male cortical explants, ER! mRNA expression increased in cortical
explants across time in culture (1 to 22 DIC), but treatment in the feed media is
not a factor. For the male explants grown in media containing vehicle and E2, a
two-way ANOVA comparing the factors “treatment” and “DIC” revealed a
significant main effect of DIC (p< 0.0001, F= 8.718, df= 3, 63), but no main effect
of treatment and no interaction. To determine which DIC were different a
Student Newman-Keuls post-hoc test was conducted and revealed that ER!
mRNA expression significantly increased at 15 and 22 DIC compared to 1 and 7
DIC (p< 0.05) (Figure 2.10). These significant differences include data from both
vehicle and E2 treated male cortical explants because there was not an effect of
treatment. Overall, male cortical explants had an increase in ER! mRNA
expression across time in culture.
To look at relative levels of mRNA expression, not a change compared
back to 1 DIC, the ratio of housekeeping Ct values (average specific 1 DIC
housekeeping Ct value/ sample housekeeping Ct value) was multiplied by the Ct
value for the gene of interest for the same sample, Table 2.8. I have included
average Ct values for ER! and His 3.1 for female and males at each time-point,
Table 2.8. This chart highlights ER! Ct values normalized to average histones
that can be compared across PND. For the female and male cortex, ER! Ct
values showed that there was a decrease in mRNA expression across time in
culture. The graphs, Figure 2.9-2.10, have Ct values logarithmically expressed
relative to PND 4; however, the table has raw ER! Ct values normalized to
average histone Ct values that can be compared across 1 DIC. The chart Ct
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values show a substantial change in Ct values that are less than 30. For real
time PCR, the lower the Ct values the more mRNA and changes that are less
than 30 are considered “real.” Ct values greater than 30 occur during the plateau
phase of the logarithmic PCR cycle where there is an increase chance of error
(reviewed in (Wong and Medrano 2005)). The chart Ct values correspond to the
logarithmic change seen in the graphs. For the female and male cortex, ER! Ct
values showed an increase across DIC.

!

63

Relative levels of ER Beta mRNA

ER Beta mRNA Expression
In Male Cortical Explants
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Figure 2.10. ER! mRNA expression in male cortical explants. ER! mRNA
increased across time in culture in vehicle and E2-treated male cortical explants.
The graph above shows ER! relative to the housekeeping gene histone 3.1. Ct
values from each postnatal day are compared to 1 DIC for each media treatment.
Asterisk on the graph indicate significant increases from PND 4, p<0.05. The
letter “a” on the graph indicates significant increases from PND 10, p< 0.05.
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Table 2.8. Average real time PCR Ct values from housekeeping gene
histone 3.1 and ER! in cortical explants grown for 1, 7, 15 and 22 days in
culture (DIC). Bolded box on table A and B (females) and table C and D (males)
indicates ER! Ct values normalized to average histones for each postnatal day.
Note: higher Ct values indicate a lower expression level of mRNA by
representing a greater number of PCR cycles to reach a maximum.
A.
EtOH Treated Average Ct Value Ct value normalized to
average histone
Sex
PND
Histone
ER beta
18.94
30.16
4
30.83
19.98
31.41
10
30.61
Female
20.27
29.57
18
29.59
19.74
29.46
25
29.53
B.
Sex

PND

Female

4
10
18
25

E2 Treated Average Ct Value
Histone
ER beta
19.28
30.20
18.44
32.99
19.82
28.62
19.45
29.03

Ct value normalized to
average histone

EtOH Treated Average Ct Value
Histone
ER beta
19.67
30.47
19.97
30.64
20.29
29.22
20.14
29.19

Ct value normalized to
average histone

E2 Treated Average Ct Value
Histone
ER beta
19.04
31.9
20.45
30.21
19.51
29.81
19.51
39.91

Ct value normalized to
average histone

29.62
30.60
28.68
29.10

C.
Sex

PND

Male

4
10
18
25

30.49
30.16
29.17
29.36

D.

!

Sex

PND

Male

4
10
18
25
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31.93
30.46
30.01
29.58

AR
Does E2 influence AR mRNA expression in rat cortical explants
across time in culture?
We analyzed mRNA expression by statistically comparing treatment
(EtOH and E2) and days in culture (DIC) separately for female cortical explants
and male cortical explants. AR mRNA expression significantly increased in
female and male cortical explants that were EtOH and E2 treated.
In female cortical explants, AR mRNA expression increased across time in
culture (1 to 22 DIC), but treatment in the feed media is not a factor. For the
female explants grown in media containing vehicle and E2, a two-way ANOVA
comparing the factors “treatment” and “DIC” revealed a significant main effect of
DIC (p< 0.0001, F= 11.610, df= 3, 65), but no main effect of treatment and no
interaction. To determine which DIC were different a Student Neuman-Keuls
post-hoc test was conducted and revealed that AR mRNA expression was
significantly increased at 15 and 22 DIC compared to 1 and 7 DIC (p< 0.05),
Figure 2.11.
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AR mRNA Expression
In Female Cortical Explants
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Figure 2.11. Androgen receptor mRNA expression in female cortical
explants. AR mRNA increased across time in culture in vehicle and E2-treated
cortical explants. The graph above shows AR relative to the housekeeping gene
histone 3.1. Ct values from each postnatal day are compared to 1 DIC for each
media treatment. Asterisk on the graph indicate significant increases from PND
4, p<0.05. The letter “a” on the graph indicates significant increases from PND
10, p< 0.05.
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In male cortical explants, AR mRNA expression increased across time in
culture (1 to 22 DIC) and E2 did influence the expression. For the male explants
grown in media containing vehicle and E2, a two-way ANOVA comparing the
factors “treatment” and “DIC” revealed a significant main effect of DIC (p<
0.0001, F= 11.093, df= 3, 58), but no main effect of treatment and no interaction.
To determine which DIC were different a Student Newman-Keuls post-hoc test
was conducted and revealed that AR mRNA expression significantly increased at
15 and 22 DIC compared to 1 and 7 DIC and 15 DIC to 22 DIC (p< 0.05), Figure
2.12. These significant differences include data from both vehicle and E2 treated
male cortical explants because there was not an effect of treatment. Overall,
male cortical explants had an increase in AR mRNA expression.
To look at relative levels of mRNA expression, not a change compared
back to 1 DIC, the ratio of housekeeping Ct values (average specific 1 DIC
housekeeping Ct value/ sample housekeeping Ct value) was multiplied by the Ct
value for the gene of interest for the same sample, Table 2.9. I have included
average Ct values for AR and His 3.1 for female and males at each time-point,
Table 2.9. This chart highlights AR Ct values normalized to average histones
that can be compared across PND. For the female and male cortex, AR Ct
values showed that there was a decrease in mRNA expression across time in
culture. The graphs, Figure 2.11-2.12, have Ct values logarithmically expressed
relative to 1 DIC; however, the table has raw AR Ct values normalized to average
histone Ct values that can be compared across 1 DIC. The chart Ct values show
a substantial change in Ct values that are less than 30. For real time PCR, the
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lower the Ct values the more mRNA and changes that are less than 30 are
considered “real.” Ct values greater than 30 occur during the plateau phase of
the logarithmic PCR cycle where there is an increase chance of error (reviewed
in (Wong and Medrano 2005)). The chart Ct values correspond to the
logarithmic change seen in the graphs. For the female and male cortex, AR Ct
values showed an increase across DIC.
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AR mRNA Expression
In Male Cortical Explants
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Figure 2.12. Androgen receptor mRNA expression in male cortical explants.
AR mRNA increased across time in culture in vehicle and E2-treated male
explants.The graph above shows AR relative to the housekeeping gene histone
3.1. Ct values from each postnatal day are compared to 1 DIC for each media
treatment. Asterisk on the graph indicate significant increases from PND 4,
p<0.05. The letter “a” on the graph indicates significant increases from PND 10,
p< 0.05. The letter “b” on the graph indicates significant increases from PND 18,
p< 0.05.
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Table 2.9 Average real time PCR Ct values from housekeeping gene histone
3.1 and AR in cortical explants grown for 1, 7, 15 and 22 days in culture
(DIC). Bolded box on table A and B (females) and table C and D (males)
indicates AR Ct values normalized to average histones for each postnatal day.
Note: higher Ct values indicate a lower expression level of mRNA by
representing a greater number of PCR cycles to reach a maximum.
A.
EtOH Treated Average Ct Value
Ct value normalized
Sex
DIC
to average histone
Histone
AR
18.94
32.33
1
32.54
18.71
30.83
7
30.37
Female
20.27
28.38
15
28.42
19.9
29.33
22
29.58
B.
Sex

DIC

Female

1
7
15
22

Estrogen Treated Average Ct Value
Histone
AR
19.25
31.20
18.45
31.82
19.68
27.58
19.45
28.98

Ct value normalized
to average histone

EtOH Treated Average Ct Value
Histone
AR
19.77
32.18
19.38
29.22
19.77
28.29
20.13
28.04

Ct value normalized
to average histone

Estrogen Treated Average Ct Value
Histone
AR
19.04
33.34
20.1
29.99
19.57
28.69
19.51
29.03

Ct value normalized
to average histone

31.57
30.47
27.61
29.10

C.
Sex

DIC

Male

1
7
15
22

33.15
29.47
27.03
28.24

D.
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Sex

DIC

Male

1
7
15
22
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33.60
30.72
28.89
27.66

Discussion
In these studies, I compared expression of three sex steroid hormone
receptors, ER alpha (ER!), ER beta (ER") and androgen receptor (AR) in the rat
cortex and in cortical explants taken from male and female rats. My first goal
was to test the hypothesis that these sex steroid hormone receptors were
regulated similarly during postnatal development that was previously published in
the mouse.

My second goal was to test the hypothesis that these sex steroid

hormone receptors change across time in culture in rat cortical explants when the
cortex is isolated away from other regions of the brain. By understanding the
expression patterns of steroid hormone receptors during postnatal development,
we can potentially understand how they are regulated at other times during an
animal’s lifetime due to the theory that the brain reverts back to its developmental
state to aid in repair following brain injury (Emery, Royo et al. 2003).
As expected in the female and male rat cortex, ER! mRNA expression
significantly decreased, ER" mRNA expression significantly increased and AR
mRNA expression also significantly increased all compared to a housekeeping
gene across early postnatal development, Table 2.10. This confirms our
hypothesis that the mRNA for these sex steroid hormone receptors changes
similarly during rat postnatal development that was previously published in the
mouse. Specifically, ER! mRNA significantly decreased at PND 18, ER" mRNA
expression significantly increased at PND 25 and AR mRNA expression
significantly increased at PND 18, Table 2.10. For these sex steroid hormone
receptors there was no sex difference across postnatal development. This
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Table 2.10. Summary Table of Sex Steroid Hormone Receptors. The
expression pattern for ER!, ER" and AR mRNA across early postnatal
development in the female and male cortex and changes in expression patterns
across time in culture in cortical explants take female and male rat pups were
summarized.
Female
ER! mRNA
expression
ER" mRNA
expression
AR mRNA
expression

!

Male

Cortex

Cortical
Explants

Cortex

Cortical
Explants

#

#

#

#

$

$

$

$

$

$

$

$
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follows a similar pattern of what was previously published (Prewitt and Wilson
2007).
As expected in cortical explants taken from either female or male rats,
ER! mRNA expression significantly decreased, ER" mRNA expression
significantly increased and AR mRNA expression also significantly increased
across time in culture, Table 2.10. This confirms our second hypothesis that
these sex steroid hormone receptors would change across time in culture. This
validates the explant model by showing the cortex, when isolated away from
other regions of the brain, can maintain its dynamic regulation of the sex steroid
hormone receptors mRNA expression. Specifically, ER! mRNA significantly
decreased in female cortical explants at 7 DIC, regardless of treatment, Figures
2.7. However, when vehicle and E2-treated males explants were compared
there was a significant effect of treatment, where E2 treatment decreased ER!
mRNA expression compared to vehicle treatment. There was also a significant
decrease in ER! mRNA expression at 22 DIC in male cortical explants, Figure
2.8. Sex differences cannot be compared directly because female and male
cortical explants were not analyzed directly. They were compared within sex
looking at the effect of treatment. In female cortical explants, ER! mRNA
expression significantly decreased at 7 DIC, where male cortical explants did not
have a significant decrease until 22 DIC. E2 also decreased ER! mRNA
expression in males, but did have an effect in female cortical explants.
ER" mRNA significantly increased at 15 DIC when vehicle and E2 treated
female or male explants are compared independently, Figures 2.9-2.10. AR
!
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mRNA expression significantly increased at 15 DIC, regardless of sex or
treatment.
The additional presence of E2 in the feed media only alters ER! mRNA
expression in only male cortical explants. This could be due to a change in the
hormonal environment that the male cortical explants experience from the time of
plating that is different from in the intact brain, in vivo. Males do not have alphafetal protein to bind to E2 and prevent it from crossing the blood brain barrier.
Therefore E2 masculinizes the brain in male rodents. The E2 concentration in
the intact cortex may vary from the E2 concentration in the feed media, which
causes ER! mRNA expression to be lower compared its vehicle control. Since
ER! is high while ER" and AR mRNA expression are low at the time of plating,
ER! mRNA expression could be more susceptible to an alteration in hormonal
environment and decrease in mRNA expression with the presence or change in
concentration of E2.
Sex steroid hormone protein expression was not correlated to the mRNA
expression. Protein, not mRNA, expression can directly correlate to function.
Changes in ER!, ER" and AR mRNA expression have been correlated to
changes in protein expression. Ideally protein and mRNA expression would have
been measured across early postnatal development in the intact cortex and
across time in culture in cortical explants instead of just mRNA expression.
However due to lack of specificity in antibodies for ER" and AR western blots
(Skliris, Parkes et al. 2002) (Snyder, Smejkalova et al. 2010), protein expression
could not be accurately measured. Specifically, ER" protein was detected in an
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ER! knockout where there was no ER! expressed (Snyder, Smejkalova et al.
2010).
The cytoarchitecture of the cortex is known to change and mature during
postnatal development. Steroid hormones and their receptors influence this
cytoarchitecture by influencing synaptogenesis (Mong, Roberts et al. 2001), cell
differentiation (De Vries, Rissman et al. 2002; Simerly 2002), apoptosis (Chung,
Swaab et al. 2000; Forger 2006), neurite outgrowth (Toran-Allerand 1976; ToranAllerand 1976), connectivity and migration (Parent, Naveau et al. 2011; Peper,
Hulshoff Pol et al. 2011; Peper, van den Heuvel et al. 2011). Specifically the
higher expression of ER! and AR that occurs from postnatal day 18 to 25
correlates with steroidogenesis that is beginning in the sex organs during the
second postnatal week (Carson and Smith 1986; Dufau, Khanum et al. 1987).
The brain is sexual differentiated around PND 18 when an enzyme (aromatase)
that converts testosterone, from steroidogenesis in males, to estrogen is present
(Green and Simpkins 2000). Estrogen produced from steroidogenesis in females
is bound to alpha-fetoprotein, which inhibits its access across the blood brain
barrier (Keller, Pawluski et al. 2010). However, the male brain is masculinized by
the presence of estrogen and the lack of alpha-fetoprotein (Keller, Pawluski et al.
2010). Although the male brain is believe to be masculinized by estrogen and
the female brain by the lack there of, the amount of de novo estrogen production
is variable. The enzymes for de novo estrogen production are present
throughout development (Ibanez, Guennoun et al. 2003; Tsutsui 2008;
Nagarajan, Tsai et al. 2011) and can be compensating for the presence of alpha-
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fetoprotein by locally producing estrogen in the female brain. The first two weeks
of postnatal development in the cortex are when cells are migrating and forming
neuronal circuits within the cortex and with other regions of the brain. The
increase in steroid hormones and their receptors correlated with the cellular
organization of the cortex. Disruption of these hormones and receptors cause
delays in cell death and disruption in cytoarchitecture (Nunez, Jurgens et al.
2000; Nunez, Lauschke et al. 2001; Nunez, Huppenbauer et al. 2003). The
concentrations of hormones present across postnatal development vary
depending on brain region. For example, the hypothalamus had higher E2
concentrations than the cortex, which had higher concentrations than the
hippocampus. These changes in E2 concentration that occurred in the brain
across the first 10 days of life were not sex specific in the hypothalamus or the
hippocampus. However, there were sex differences in E2 concentration in the
cortex. Specifically, males had a peak concentration of E2 in the cortex on PND
4, while females did not peak until PND 6. Following the initial sex difference in
days when E2 concentrations peaked, both sexes had a similar pattern of
decrease in E2 across postnatal development. Interestingly, females and males
that were adrenalectomized and gonadectomized before they were 12 hours old,
also maintained a similar hormonal pattern in the brain to animals with intact
adrenal glands and gonads when they were 3 days old. These data
demonstrated that the brain regulates hormone concentrations independently of
the rest of the body. This may be a protective mechanism to ensure the brain
receives a certain amount of hormones independently of the body to ensure
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proper brain development. Cortical explants also appear to be maintaining
homeostasis by regulating sex steroid hormone receptor expression when
changes occur in the hormone environment, such as a difference in ER! mRNA
expression seen in male cortical explants in the presence of E2.
ER! mRNA expression, in female cortical explants, significantly
decreases earlier (7 DIC) than intact cortex. In male cortical explants, ER!
mRNA decreased later (22 DIC) compared to the intact cortex (PND 18).
Changes in ER" mRNA expression were also seen earlier in cortical explants, 15
DIC, than across cortical development. AR has a similar increase in mRNA
expression in cortical explants, 15 DIC, and in vivo, PND 18. In general, cortical
explants had a similar change in expression in ER!, ER" and AR that is seen in
cortical development, in vivo. However, generally we see a significant change in
mRNA expression earlier when cortical explants are grown in culture. This could
be due to numerous possibilities. One possibility is a lack of inhibitory cues from
other parts of the brain such as the striatum, a region of the brain that located
directly next to the cortex (Figure 2.1). The axons from the cortex not only
project into the striatum and back into the cortex, but also to the thalamus and
brainstem (Rosell and Gimenez-Amaya 1999; Hooks, Hires et al. 2011; Mao,
Kusefoglu et al. 2011).
Another possibility is the change of nutrients that the cortical explants
receive compared to the cortex during development. In cortical development
there is a vast blood supply with numerous growth factors. Cortical explants are
isolated from this blood supply and grown on millicell membranes with access to
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feed media. So it is important to note that while there are differences we can
correlate the overall expression patterns. The changes that occur across time in
culture will allow us to evaluate steroid hormones and how they affect steroid
hormone receptors across development and following injury.
One limitation of the cortical explant model is determining the relative age
of the cortical explant. The explants are taking out of a PND 3 rat pup and
allowed to “age” in culture. When the organization of the neurons and glia cells
in the cortex of mature animals are compared to explants taken from PND3 rat
pups and “aged,” the glia and neuronal cells due not exhibit the same pattern of
organization (Staal, Alexander et al. 2011). Explants isolated from neonatal
animals and grown in culture have increased glia expression and loss of
cytoarchitectural neuronal organization of the different layers of the cortex
compared to the cortex taken from a mature animal (Staal, Alexander et al.
2011). Aged cortical explants have a loss of glia limitans and display additional
growth on the periphery of slice from possible progenitor like cells (Staal,
Alexander et al. 2011). The have, however, been shown to be a reliable model
for studying injury (Wise, Dubal et al. 2000; Wilson, Liu et al. 2002)
The cortical explant model allows us to look at a specific region of the
brain, the cortex, with out input from other regions of the brain. This is important
because the cortex is a region of the brain that is protected by estrogen following
injury. This model allows us to isolate the cortex and look at changes across
development and to simplify an injury and determine if the neuroprotection is
endogenous to the cortex or if the cortex requires input from other regions of the
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brain. The explant model is unique because it is a heterogeneous population of
neurons and glial cells that other in vitro models do not incorporate. The
neuronal glial cross talk is essential to take into consideration in any model of the
brain because these cells work together in development and in injury.
The expression of 3 sex steroid hormone receptors ER!, ER" and AR
were described across postnatal development in the cortex and across time in
culture in cortical explants. My first hypothesis was confirmed that these sex
steroid hormone receptors were regulated similarly during postnatal development
that was previously published in the mouse.

My second hypothesis was also

confirmed that these sex steroid hormone receptors also change across time in
culture in rat cortical explants. By understanding the expression patterns of
steroid hormone receptors during postnatal development, we can potentially
understand how they are regulated at other times during an animal’s lifetime, ie
following brain injury. Specifically the cortical explant model will allow us to
evaluate mechanism of neuroprotection inside the cortex and allow us to
pharmacologically manipulate only the cortex to further outline the mechanisms
involved in neuroprotection.
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CHAPTER 3
SEX DIFFERENCES AND ESTROGEN-MEDIATED NEUROPROTECTION IN
MODEL OF ISCHEMIA

Introduction
Brain ischemia occurs when the brain is deprived of blood flow, which
results in an inadequate supply of oxygen and glucose. Tissues need oxygen
and glucose to meet their metabolic cellular demands. Insufficient blood supply
for seconds in the brain can result in cell death and tissue damage. This
ischemia-induced cell death is only one type of stroke, but occurs the majority
(87%) of the time, while the other 13% of strokes are hemorrhagic (Roger, Go et
al. 2012). Ischemia can be classified as focal, which is confined to a specific
region of the brain, or global, which involves wide areas of brain tissue. Our lab
has used an animal model to study focal ischemia caused by middle cerebral
artery occlusion (MCAO). As described in the General Introduction, MCAO
causes a significant reduction in cerebral blood flow to the striatum and over
laying cortex (Dubal, Kashon et al. 1998). This decrease in blood supply leads to
necrotic cell death in the striatum followed by apoptotic cell death in the over
laying cortex (Liu, Smith et al. 1999).
The effects of ischemic cell death are heavily influenced by an animal’s
steroid hormone background. Following MCAO, gonadectomized females
(Simpkins, Rajakumar et al. 1997; Dubal, Kashon et al. 1998; Toung, Traystman
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et al. 1998; Rusa, Alkayed et al. 1999; Dubal and Wise 2001) and males (Toung,
Traystman et al. 1998; Uchida, Palmateer et al. 2009) have a much larger
MCAO-induced injury than animals with higher circulating estrogen
concentrations. Pretreatment with even low doses of E2 is sufficient to exert
dramatic protection in the brains of both female (Dubal, Kashon et al. 1998;
Dubal and Wise 2001) and male rats (Toung, Traystman et al. 1998). In
humans, the role of hormone replacement is not as clear. In fact, some clinical
studies found that estrogens were not beneficial at all (Wilson, Garrison et al.
1985; Grodstein, Stampfer et al. 1996; Petitti, Sidney et al. 1998; Anderson,
Limacher et al. 2004), while other studies did report benefits following stroke
(reviewed in (Behl 2002; McCullough and Hurn 2003)). The discrepancies
between different studies may in part be explained by differences in the timing of
estrogen replacement and the age of women included in the studies. As
described above, animal studies are much less controversial and provide a
simpler model to study the mechanisms of neuroprotection by E2 following
ischemic brain injury.
An important factor in the extent of brain damage following ischemic injury
in animal models is the level and expression pattern of estrogen receptors (ER).
For example, generalized pharmacologic blockade of ER exacerbates ischemic
injury in mice (Sawada, Alkayed et al. 2000) and blocks estrogen-induced
neuroprotection in cultured neurons (Singer, Figueroa-Masot et al. 1999; Wilson,
Dubal et al. 2000) and in cortical explant cultures (Wilson, Dubal et al. 2000).
Specifically, ER! and not ER" seem to be very important, while AR has not been
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evaluated. Studies using ER! knockout females demonstrate that
neuroprotection by E2 following ischemia is dependent on the presence of ER!
in the cortex (Dubal, Zhu et al. 2001), and that ER" alone is not sufficient for
neuroprotection in females. As described in chapter 2, ER! is only transiently
expressed in the cortex during early postnatal development and then is virtually
absent in the uninjured adult cortex (Miranda and Toran-Allerand 1992; Prewitt
and Wilson 2007). 24 hours after MCAO, however, ER! mRNA and protein are
increased in the cortex of female rats and mice (Dubal, Shughrue et al. 1999;
Dubal, Rau et al. 2006). In OVX females, the increase in ER! mRNA occurs in
both oil and E2-treated groups, but is seen earlier after injury with E2 (Dubal,
Rau et al. 2006). These data suggest that in females, the ischemia-induced
increase in ER! in the cortex is necessary for the neuroprotective effects of E2.
Interestingly, although male rodents can be protected by E2 (depending on the
concentration and time frame of treatment), ER! expression did not change
following injury in gonadally intact males (Westberry, Prewitt et al. 2008). The
previous animal studies show a clear role for E2 and estrogen receptors in
neuroprotection following MCAO. This model is quite complicated and does not
allow us to focus on understanding mechanisms specific to the cortex.
For the studies included in this chapter, I will use the in vitro cortical
explant model described in chapter 2 as a simplified way to discern sex-specific
mechanisms of neuroprotection that are innate to the cortex. This model is better
than using isolated neuronal cultures because it maintains the important
neuronal/glial relationship. Here, cortical cultures were separated based on sex
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and treated with 2-deoxyglucose and potassium cyanide (2DG-KCN) to block
glycolysis and oxidative phosphorylation, which simulates ischemia. Previous
studies from our lab have used this model to study injury by treating cortical
explants grown for one week in culture with 2DG-KCN and showed that
pretreatment of E2 attenuated this cell death (Wilson, Dubal et al. 2000; Wilson,
Liu et al. 2002). Those studies did not look at sex-specific changes in cell death
or response of receptors. With our current knowledge of sex differences in cell
death and changes in receptors with response to injury, we felt it essential to
repeat those studies separating cortical explants from female and male pups.
In the first part of this chapter, I wanted to test the hypothesis that
2DG/KCN treatment increased cell death and determine if increased cell death
occurred in a sex-specific manner. I also wanted to measure the influence of E2
pre-treatment on 2DG/KCN induced cell death. In the second part of the chapter,
the experiments were designed to determine how injury affects steroid hormone
receptor expression and how E2 influenced changes in expression. To
accomplish these goals, I evaluated cell death by measuring propidium iodide
uptake and measured changes in sex steroid hormone receptors following
treatment with 2DG/KCN in both female and male cortical explants separately.
By understanding the mechanisms of E2 neuroprotection in cortical explants and
the regulation and expression patterns of steroid hormone receptors following
injury, I plan to pharmacologically manipulate this protection in the explants to
outline pathways that are involved.
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Methods

Injury
To induce an ischemic like injury, explants were treated with 1 mM 2-DG
(D8375, Sigma-aldrich, Saint Louis, MO) and 0.5 mM KCN (207810, Sigmaaldrich, Saint Louis, MO) for 2 hours, 2 mM 2-DG and 1 mM KCN for 2 hours or 2
mM 2-DG and 1 mM KCN for 1 hour in 1X Basal Medium Eagle, BME, (injury) or
BME (control). 2DG/KCN chemically mimics “ischemic” conditions by inhibiting
glycolysis and oxidative phosphorylation (Wilson, Liu et al. 2002). Following
injury, media was replaced. At several time-points after injury (4, 8, 12 and 24
hours), explants were processed for RNA isolation or treated with propidium
iodide to determine the extent of cell death.

Cell Death
To measure cell death, explants were washed with 0.1 M PBS and
incubated with 5 !g/ml of propidium iodide (PI) (P4170, Sigma-Aldrich, Saint
Louis, MO) (stock concentration of 1mg/mL in H2O) in BME for 30 minutes at 4,
8, 12 and 24 hours following injury. The PI was washed off with 0.1M PBS.
Explants were visualized using a fluorescent microscope. PI entered cells that
had a porous cell membranes, indicating damage, and bound to DNA. PI uptake
indicated cell death and fluoresced red (emission at 630 nm) under green light
(excited at 495 nm). Pictures, 20X magnification of explants, were captured
using an image capture program, SPOT Advanced. Red (dead) cells per frame
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were then counted using a NIH program, Image J. Pictures were coded and
analyzed blindly. Injured explants were compared back to the corresponding
vehicle treated non-injury for each hour and sex.

Statistics
For the cell death (described above) and mRNA (described in chapter 2
methods) studies, 3 litters were used to dissect female and male cortical
explants. These explants were grown in media containing 0.01% EtOH or 1 nM
E2 in 0.01% EtOH for 1 week (7 days). At least 3 explants per condition at each
time-point following injury were collected and repeated at least 3 times. For
example, 3 female explants were analyzed that were EtOH treated and injured 4
hours from the time of collection, N=1. This was repeated at least 3 times with a
new set of litters each time.
The effect of treatment and injury was determined by a two-way ANOVA
comparing the factors “treatment” (EtOH or E2) and “injury” (non injured or
2DG/KCN treated) evaluated at various time-points following injury (4, 8, 12 and
24 hours). This allowed us to determine if treatment had an effect on the PI or
mRNA expression or if injury had an effect on the PI or mRNA expression in
either female or male cortical explants. If a significant interaction between
treatment and injury was detected, Student Neuman-Keuls post-hoc tests were
performed.
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Results
Initially, three different injury paradigms were tested to determine which
concentration of 2DG/KCN to apply and how long to apply the injury. My
preliminary data on the previously published injury (2 mM 2-DG and 1 mM KCN
for 2 hours) (Wise, Dubal et al. 2000; Wilson, Liu et al. 2002) did not consistently
produce a visible injury in the explants when female and males were separated.
Since this concentration had previously injured the explants, we hypothesized
that when explants were separated based on sex they were more susceptible to
injury causing a faster and harsher cell death with 2DG/KCN. The explants did
not appear healthy and most of the cell death appeared to have washed away
when we changed media indicating an overpowering injury. To weaken the injury
we cut the concentration in half and the time the injury was applied in half. Both
injuries that were halved either in concentration or time resulted in consistent
injury. We decided to continue with the injury, 1 mM 2-DG and 0.5 mM KCN for
2 hours, which halved the original concentration of 2 mM 2-DG and 1 mM KCN
for 2 hours, because this was the lowest concentration that still consistently
injured both the female and male cortical explants. The concentration of injury in
the remaining studies is 1 mM 2-DG and 0.5 mM KCN for 2 hours.

Part 1: Cell Death in female or male cortical explants following injury.
Cortical explants were isolated from postnatal day 3 (PND 3) female or
male rat pups and grown for 7 days in culture with media containing either 17 !estradiol (E2) (1 nM in 0.01% EtOH) or EtOH (0.01%) vehicle. Explants were
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treated with 1 mM 2-DG and 0.5 mM KCN for 2 hours in BME (injury) or BME
(control). Following the 2 hour injury, media was replaced. At several time-points
after injury (4, 8, 12 and 24 hours), explants were stained with propidium iodide
to determine the extent of cell death.

Does E2 influence cell death at 4, 8, 12 or 24 hours following 2DG/KCN
treatment in female or male cortical explants?
In females there was no effect of 2DG/KCN induced injury or E2 treatment
on cell death 4, 8 or 12 hours following injury (determined by two-way ANOVA’s
at each time-point (4 hours, Figure 3.1A) (8 hours, Figure 3.2A) (12 hours, Figure
3.3A). However, 2DG/KCN produced a significant increase in cell death at 24
hours (main effect of injury; p< 0.0001, F= 24.369, df= 1, 76). A two-way ANOVA
showed an interaction between injury and treatment (p<0.05, F= 4.350, df= 1,
76). Post-hoc t-tests revealed that cell death was significantly increased
following 2DG/KCN injury in the EtOH group (p<0.05 compared to EtOH noninjured), and significantly increased following 2DG/KCN injury in the E2 group
(p<0.05 compared to EtOH non-injured) (Figure 3.4A). Interestingly, this increase
in cell death from 2DG/KCN was attenuated by the pretreatment of E2 (p<0.05,
compared to EtOH 2DG/KCN injured), (Figure 3.4A).
In males there was no effect of injury or treatment on cell death 4 or 8
hours following 2DG/KCN injury (4 hours, Figure 3.1B) (8 hours, Figure 3.2B).
However, 2DG/KCN produced a significant increase in cell death at 12 hours
(main effect of injury; p= 0.0322, F= 4.979, df= 1, 35; Figure 3.3B) and at 24
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hours (main effect of injury; p< 0.0001, F= 24.958, df= 1, 98; Figure 3.4B).
Pretreatment with E2 did not alter the amount of cell death induced by 2DG/KCN
at either time point.
Figure 3.5 depicts PI uptake (10X pictures) 24 hours following treatment
with 2DG/KCN in vehicle (EtOH) and E2-treated female and male cortical
explants. Overall, male cortical explants exhibited earlier increases in cell death
in response to 2DG/KCN injury than females. E2 attenuated the 2DG/KCN
induced cell death in female, but not male, cortical explants.
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A.

B.

Figure 3.1. Cell death 4 hours following injury with 2DG/KCN in cortical
explants. At 4 hours there was not a significant increase in cell death with
2DG/KCN in female (A) or male explants (B) or an effect of E2. The graphs
above show PI uptake in non-injured (light pink (A) or light blue (B) bars) and
2DG/KCN-injured (pink (A) or blue (B) bars) cultures for vehicle or estrogen
treatment. Error bars represent SEM.
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A.

B.

Figure 3.2. Cell death 8 hours following injury with 2DG/KCN in cortical
explants. At 8 hours there was not a significant increase in cell death with
2DG/KCN in female (A) or male explants (B) or an effect of E2. The graphs
above show PI uptake in non-injured (light pink (A) or light blue (B) bars) and
2DG/KCN-injured (pink (A) or blue (B) bars) cultures for vehicle or estrogen
treatment. Error bars represent SEM.
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A.
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Figure 3.3. Cell death 12 hours following injury with 2DG/KCN in cortical
explants. (A). At 12 hours, there was not an effect of 2DG/KCN injury or an
effect of E2 in female cortical explants. (B). In male explants, at 12 hours there
was a significant increase in cell death with 2DG/KCN injury, but no effect of E2.
The graphs above show PI uptake in non-injured (light pink (A) or light blue (B)
bars) and 2DG/KCN injured (pink (A) or blue (B) bars) cultures for vehicle or
estrogen treatment. Error bars represent SEM.
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Figure 3.4. Cell death 24 hours following injury with 2DG/KCN in cortical
explants. (A). In female explants, there was significant increase in cell death with
2DG/KCN injury. E2 significantly decreased this 2DG/KCN induced cell death.
(B). In male explants, there was a significant increase in cell death with
2DG/KCN, but no effect of E2. The graphs above show PI uptake in non-injured
(light pink (A) or light blue (B) bars) and 2DG/KCN-injured (pink (A) or blue (B)
bars). Single asterisks indicate a significant increase in cell death from respective
non-injured groups and double asterisks indicate a significant difference from
vehicle-treated 2DG/KCN, p< 0.05. Error bars represent SEM.
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Male
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Figure 3.5 Representative photographs of PI uptake at 24 hours. (A). In
female explants, there was increased cell death (red dots) with 2DG/KCN
treatment. E2 significantly decreased this cell death. (B). In male explants,
there was increased cell death with 2DG/KCN, but no effect of E2 on cell death.
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Part 2: Sex steroid hormone receptor expression in female and male
cortical explants following treatment with 2DG/KCN.
Cortical explants were isolated from postnatal day 3 (PND 3) female or
male rat pups and grown for 7 days in culture with media containing either 17 !estradiol (E2) (1 nM in 0.01% EtOH) or EtOH (0.01%) vehicle. Explants were
treated with 1 mM 2-DG and 0.5 mM KCN for 2 hours in BME (injury) or BME
(control). 2DG/KCN chemically mimics “ischemic” conditions by inhibiting
glycolysis and oxidative phosphorylation (Wilson, Liu et al. 2002). Following the
2 hour injury, media was replaced. At several time-points after injury (4, 8, 12 and
24 hours), explants were collected and RNA extracted for real time PCR. Each
time-point included the collection of at least 3 explants (N=1) per well that was
repeated independently at least 3 times.

ER!
Does E2 influence ER! mRNA expression at 4, 8, 12 or 24 hours following
2DG/KCN treatment in female or male cortical explants?
In females, 2DG/KCN or E2 pretreatment did not affect ER! mRNA
expression at 4 (Figure 3.6A) or 8 hours (Figure 3.7A). However, at 12 hours
(Figure 3.8A) 2DG/KCN resulted in a significant increase in ER! mRNA
expression (main effect of injury; p=0.0011, F=15.146, df=1,18). E2 pretreatment
reduced ER! mRNA expression (main effect of treatment; p= 0.0060, F= 9.682,
df= 1,18), preferentially in the 2DG/KCN injured cultures (interaction effect;
p=0.0071, F=9.238, df=1,18).
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significantly increased by 2DG/KCN injury in EtOH treated cultures, (p<0.0001
compared to EtOH non-injured cultures; p<0.0001 compared to the E2 noninjured cultures). E2 pretreatment significantly attenuated the increase in ER!
mRNA expression due to 2DG/KCN (p<0.001 compared with EtOH 2DG/KCN
injured) to a level equivalent to that in uninjured E2 treated cultures.
Interestingly, by 24 hours ER! mRNA expression had returned to baseline
(Figure 3.9A; no effect of injury, p=0.9570, F=0.003, df=1,29 and no effect of
treatment; p=0.6942, F=0.158, df= 1,29).
Neither 2DG/KCN nor E2 pretreatment affected ER! mRNA expression at
4 (Figure 3.6B), 8 (Figure 3.7B), or 12 (Figure 3.8B) hours in male cortical
explants. Interestingly, 2DG/KCN significantly reduced ER! mRNA expression in
male cortical explants at 24 hours (main effect of injury, p= 0.0290 F=5.830, df=1,
15) (Figure 3.9B).
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Figure 3.6. ER! mRNA expression 4 hours after injury. There was no
significant increase in ER! mRNA expression with 2DG/KCN injury or E2
pretreatment in either the (A). female or (B). male explants. The graph above
shows ER! relative to the housekeeping gene histone 3.1 in non-injured (light
purple (A) and light teal (B) bars) and 2DG/KCN treated (purple (A) and teal (B)
bars) cultures. Error bars represent SEM.
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A.

B

Figure 3.7. ER! mRNA expression 8 hours after injury. There was no
significant increase in ER! mRNA with 2DG/KCN injury or E2 pretreatment in
either the (A). female or (B). male explants. The graph above shows ER!
relative to the housekeeping gene histone 3.1 in non-injured (light purple (A) and
light teal (B) bars) and 2DG/KCN treated (purple (A) and teal (B) bars) cultures.
Error bars represent SEM.
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Figure 3.8. ER! mRNA expression 12 hours following injury. (A). In female
explants ER! mRNA expression increased following 2DG/KCN injury in vehicletreated cortical explants, indicated by an asterisks. E2 treatment prevented this
increase, indicated by an “a” on the graph. (B). In males, there was no significant
2DG/KCN injury or E2 induced difference in ER! mRNA expression. The graph
above shows ER! relative to the housekeeping gene in non-injured (light purple
(A) and light teal (B) bars) and 2DG/KCN injured (purple (A) and teal (B) bars)
cultures. Asterisks indicate a significant increase in ER! mRNA expression from
vehicle non-injured group and the letter “a” indicates a significant decrease from
vehicle 2DG/KCN injured cultures, p< 0.05. Error bars represent SEM.
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Figure 3.9. ER! mRNA expression 24 hours following injury. (A). In
females, there was no significant change in ER! mRNA expression. (B). In
males, ER! mRNA expression was significantly decreased 24 hours following
injury with 2DG/KCN. The graph above shows ER! relative to the housekeeping
gene in non-injured (light purple (A) and light teal (B) bars) and 2DG/KCN injured
(purple (A) and teal (B) bars) cultures. Error bars represent SEM.
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ER!
Does E2 influence ER! mRNA expression at 4, 8, 12 or 24 hours following
2DG/KCN treatment in female or male cortical explants?
Two-way ANOVAs comparing the factors injury and treatment were
conducted at each time-point, separately for females and males. There was no
effect of E2 treatment or 2DG/KCN injury on ER! mRNA expression at 4 (Figure
3.10), 8 (Figure 3.11), 12 (Figure 3.12) or 24 (Figure 3.13) hours in female or
male cortical explants.
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Figure 3.10. ER beta mRNA expression 4 hours after injury. There was no
significant difference in ER! mRNA expression at 4 hours after injury in (A).
female or (B). male explants. The graph above shows ER! relative to the
housekeeping gene histone 3.1 in non-injured (pink (A) and grey (B) bars) and
2DG/KCN treated (orange (A) and black (B) bars). Error bars represent SEM.
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Figure 3.11. ER beta mRNA expression 8 hours after injury. There was no
significant difference in ER! mRNA expression at 8 hours after injury in (A).
female or (B). male explants. The graph above shows ER! relative to the
housekeeping gene histone 3.1 in non-injured (pink (A) and grey (B) bars) and
2DG/KCN treated (orange (A) and black (B) bars). Error bars represent SEM.
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Figure 3.12. ER beta mRNA expression 12 hours after injury. There was no
significant difference in ER! mRNA expression at 12hours after injury in (A).
female or (B). male explants. The graph above shows ER! relative to the
housekeeping gene histone 3.1 in non-injured (pink (A) and grey (B) bars) and
2DG/KCN treated (orange (A) and black (B) bars). Error bars represent SEM.
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Figure 3.13. ER beta mRNA expression 24 hours after injury. There was no
significant difference in ER! mRNA expression at 24 hours after injury in (A).
female or (B). male explants. The graph above shows ER! relative to the
housekeeping gene histone 3.1 in non-injured (pink (A) and grey (B) bars) and
2DG/KCN treated (orange (A) and black (B) bars). Error bars represent SEM.
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AR
Does E2 influence AR mRNA expression at 4, 8, 12 or 24 hours following
injury?
In females, 2DG/KCN or E2 pretreatment did not affect AR mRNA
expression at 4 hours (Figure 3.14A). However, at 8 hours (Figure 3.15A)
2DG/KCN transiently increased AR mRNA expression in female cortical explants
(main effect of injury, p=0.0096, F=8.789, df=1,15), but this effect was not
dependent on E2 pretreatment. Interestingly by 12 hours (Figure 3.16A) AR
mRNA expression was no longer significantly increased following injury with
2DG/KCN (no effect of injury, p=0.0616, F=4.050, df= 1,16) and E2 pre-treatment
still did not affect cell death. AR mRNA expression was back down to baseline
by 24 hours (Figure 3.17A) following injury with 2DG/KCN (p=0.3880, F=791,
df=1,15), and was not dependent on E2 treatment.
In contrast, neither 2DG/KCN nor E2 pre-treatment affected AR mRNA
expression at 4 (Figure 3.14B), 8 (Figure 3.15B), 12 (Figure 3.16B) or 24 (Figure
3.17B) hours in male cortical explants.
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A.

B.

Figure 3.14. AR mRNA expression 4 hours after injury. There were no
significant differences in AR mRNA expression at 4 hours after injury in (A).
female or (B). male explants. The graph above shows AR relative to the
housekeeping gene histone 3.1 in non-injured (light pink (A) and blue (B) bars)
and 2DG/KCN treated (pink (A) and green (B) bars). Error bars represent SEM.
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Figure 3.15. AR mRNA expression 8 hours after injury. (A). In females, there
was a significant increase in AR mRNA expression following 2DG/KCN injury at 8
hours with no effect of E2 pre-treatment. (B). There was no significant effect of
2DG/KCN injury or E2 pre-treatment on AR mRNA expression in male explants.
The graph above shows AR relative to the housekeeping gene histone 3.1 in
non-injured (light pink (A) and blue (B) bars) and 2DG/KCN treated (pink (A) and
green (B) bars). Error bars represent SEM.
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A.

B.

Figure 3.16. AR mRNA expression 12 hours after injury. There were no
effects of 2DG/KCN injury or E2-pre-treatment on AR mRNA expression at 12
hours in (A). female or (B). male explants. The graph above shows AR relative
to the housekeeping gene histone 3.1 in non-injured (light pink (A) and blue (B)
bars) and 2DG/KCN treated (pink (A) and green (B) bars). Error bars represent
SEM.
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A.

B.

Figure 3.17. AR mRNA expression 24 hours after injury. There were no
effects of 2DG/KCN injury or E2-pre-treatment on AR mRNA expression at 24
hours in (A). female or (B). male explants The graph above shows AR relative to
the housekeeping gene histone 3.1 in non-injured (light pink (A) and blue (B)
bars) and 2DG/KCN treated (pink (A) and green (B) bars). Error bars represent
SEM.
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Discussion
This chapter describes cell death and sex steroid hormone receptor
expression in both male and female cortical explants following injury. In both
male and female explants, treatment with 2DG/KCN significantly increased cell
death. This increase occurred at 12 and 24 hours in males, but only at 24 hours
in females. There was also a sex difference in response to E2 pretreatment such
that in females, but not males, E2 attenuated cell death following 2DG/KCN
induced injury.
Changes in steroid hormone receptor expression following 2DG/KCN
injury were sex-specific and were influenced by E2 in the culture media,
summarized in Table 3.1 (female cortical explants) and Table 3.2 (male cortical
explants. In vehicle (EtOH) treated female cortical explants, 2DG/KCN injury
increased ER! mRNA expression at 12 hours. Interestingly, E2 pre-treatment
prevented this increase in ER! mRNA expression following the 2DG/KCN injury
in females. ER! mRNA expression was transiently increased at 12 hours and
had returned to the baseline expression by 24 hours. There was no similar
increase in ER! mRNA expression in male explants at any time-point with
2DG/KCN or E2 treatment. ER" mRNA expression did not change in response
to 2DG/KCN induced injury or with E2 pretreatment in either female or male
explants. AR mRNA expression was significantly increased with 2DG/KCN injury
at 12 hours, but had no effect of E2 pre-treatment in female cortical explants.
There was no change in AR mRNA expression due to ischemic injury induced by
2DG/KCN or E2 pre-treatment in male explants at any of the time-points.
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Table 3.1. Summary of Changes in Cell Death and Sex Steroid
Hormone Receptor mRNA Expression Following E2 Pre-treatment and
injury with 2DG/KCN in Female Cortical Explants. Female cortical explants
pre-treated with E2 were examined at 4, 8, 12 and 24 hours following an injury
with 2DG/KCN to evaluate changes in cell death and along with changes in ER!,
ER" and AR mRNA expression.

Female Cortical Explants
Non-injured
Vehicle
(EtOH)

2DG/KCN injured
E2

Vehicle
(EtOH)

E2
# from EtOH

Cell Death
(PI uptake)

No effect

No effect

# from EtOH

non-injured

non-injured

$ from EtOH
2DG/KCN

ER! mRNA
expression
ER" mRNA
expression
AR mRNA
expression

!

No effect

No effect

No effect

No effect

No effect

No effect
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# from EtOH

$ from EtOH

non-injured

2DG/KCN

No effect

No effect

# from non-

# from non-

injured

injured

Table 3.2. Summary of Changes in Cell Death and Sex Steroid Hormone
Receptor mRNA Expression Following E2 Pre-treatment and injury with
2DG/KCN in Male Cortical Explants. Male cortical explants pre-treated with E2
were examined at 4, 8, 12 and 24 hours following an injury with 2DG/KCN to
evaluate changes in cell death and along with changes in ER!, ER" and AR
mRNA expression.
Male Cortical Explants
Non-injured
Vehicle
(EtOH)
Cell Death
(PI uptake)
ER! mRNA
expression
ER" mRNA
expression
AR mRNA
expression

!

2DG/KCN injured
E2

Vehicle
(EtOH)

E2

# from non-

# from non-

injured

injured

$ from non-

$ from non-

injured

injured

No effect

No effect

No effect

No effect

No effect

No effect

No effect

No effect

No effect

No effect

No effect

No effect
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After MCAO in female rat cortex, ER! mRNA expression increases
between 4 and 16 hours (Dubal, Rau et al. 2006). In female cortical explants
treated with 2DG/KCN ER! mRNA expression significantly increased at 8 hours
and had returned to a baseline expression by 24 hours. ER! mRNA does return
to baseline following MCAO (unpublished observations), but it takes a longer
period of time. These data suggest that in both cases the ER! mRNA response
to injury is innate to the cortex, although the time course for expression is
different in each model. ER! mRNA does not increase following MCAO in male
rats (Westberry, Prewitt et al. 2008; Broughton, Brait et al. 2012) and did not
increase here in male explants at any time point after injury. In both models,
there is a sex-specific increase in ER! mRNA. It is interesting that in the cortical
explants where there are no connections to other brain regions, this sex-specific
response remains indicating that the cortex is preprogrammed as male or female
in how it responds to injury. These results may have implications for how we
treat other neurodegenerative diseases in males and females.
Following MCAO in female rat cortex, ER" mRNA expression is initially
elevated and then dramatically declines by 16 and 24 hours (Dubal, Rau et al.
2006). Pretreatment with E2 prevents the injury-induced decrease in ER" at 16
and 24 hours after injury (Dubal, Rau et al. 2006). ER" mRNA expression also
does not increase following MCAO in male rats (Westberry, Prewitt et al. 2008;
Broughton, Brait et al. 2012). Here, ER" mRNA expression did not change in
female or male cortical explants following treatment with 2DG/KCN. There is a
difference in how ER" responds to injury in the cortical explant model (in vitro)
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verse the MCAO model (in vivo) in females. Since ER! decreases in the female
cortex following injury in vivo with input and connections from other brain regions
and does not change when the cortex is isolated in culture could indicate that
changes in ER! mRNA expression in the cortex are influenced from other
regions of the brain outside the cortex.
AR mRNA was significantly increased at 12 hours following treatment with
2DG/KCN in female cortical explants and was decreased by 24 hours. AR
mRNA expression increases similarly to 2DG/KCN injury in female cortical
explants regardless of E2 treatment. In male cortical explants, AR mRNA
expression did not change following injury. These data are the first to
demonstrate sex specific changes in AR following injury in the cortex.
E2 was protective against an ischemic injury in female, but not male
cortical explants. ER" mRNA expression increased in response to injury and E2
treatment prevented this increase in ER" mRNA expression. Previously
published injury models (MCAO) show that an increase in ER" mRNA is needed
for E2-mediated protection (Suzuki, Brown et al. 2007). E2 was protective
following injury. In response to 2DG/KCN injury, ER" mRNA expression
increased and E2 treatment prevented this increase. AR mRNA expression also
increased in response to injury, but E2 did not effect the increase as it did in ER"
mRNA expression. ER! mRNA expression did not change in response to injury
or E2 treatment. Although there was not specific changes in sex steroid
hormone receptor mRNA that were associated with the E2-mediated protection,
these receptors may still play a role. E2 can also non-genomic actions.
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Signaling pathways can be initiated by receptors on the cell membrane, including
ER!, ER", AR, GPRs and ligand-gated ion channels (Watson, Jeng et al. 2008;
Roman-Blas, Castaneda et al. 2009; Liu, Zhang et al. 2012). Specifically, AKT
(serine/threonine protein kinase) becomes activated in the presence of E2 to
promote cell survival via PI3 K (phosphatidylinositide 3’OH kinase) (Wilson, Liu et
al. 2002). Pharmacological manipulations to block the activity of these receptors
will decipher the role of these receptors in E2-mediated protection.
A potential pitfall of this cortical explant model includes cell death that
occurred as a part of normal time in culture. We have investigated this cell death
and have found that we are still able to see changes associated with 2DG/KCN
damage and E2 protection. An additional limitation of this model that makes it
harder to compare to the MCAO model is that the cortex has been completely
separated from the striatum. In the MCAO model, most cortical damage is a
result of secondary cell death caused by reduced blood flow to the striatum.
Here data from our 2DG/KCN cell death must be interpreted differently, as the
cell death is primary and not a result of secondary damage.
Previously published studies using 2DG/KCN to chemical induce an
ischemic injury in cortical explants allowed the explants to maintain in culture for
7 days before adding the injury (Wise, Dubal et al. 2000; Wilson, Liu et al. 2002).
When female explants are grown for 7 days in culture ER! mRNA expression
has decreased, but males do not significantly decrease until 22 DIC. ER" and
AR mRNA expression are still low and have not increased, which occurs at 15
DIC in both female and male cortical explants. In females, all three sex steroid
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hormone receptor mRNA’s are low and in males ER! is still high. A more optimal
design would have been to injure the cortical explants with 2DG/KCN at 22 DIC
when ER! is low and ER" and AR are high, which correlates to mRNA levels
seen in the adult rodents cortex when MCAO’s are performed. To maintain
cortical explants for over three weeks in culture and then injure with 2DG/KCN
would add additional factors to our model, such as the explants are now much
thinner than at 7 DIC and the injury may affect the explants differently. The
thinner explants may be more susceptible to damage. However, because E2 is
still protective in the cortical explants grown for 7 DIC and ER! increases in
female cortical explants following injury, correlating with the MCAO data, we feel
that this model is still valuable.
Data from cortical explants will allow us to conduct more complicated
manipulations at more time-points that will translate back to the MCAO model
and allow us to use fewer animals. The cortical explant model can be furthered
utilized to describe sex differences in injury by applying pharmacological
manipulations to the cultures to block specific sex steroid hormones receptors to
see how they are involved in E2 neuroprotection.
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CHAPTER 4
ROLE OF SEX STEROID HORMONE RECEPTORS IN CELL DEATH
FOLLOWING AN ISCHEMIC INJURY

Introduction
In the previous chapters, I investigated changes in sex steroid hormone
receptor expression during development in the cortex and across time in culture
and after injury in cortical explants. This chapter will focus on the role of
endogenous sex hormone receptors following ischemic injury. Specifically, I will
use pharmacological inhibitor to block estrogen receptor alpha (ER!), estrogen
receptor beta (ER") or androgen receptor (AR) to determine the contribution of
each receptor to cell death following injury.
The cortical explant model has several advantages to evaluate the effects
of these inhibitors over adding these inhibitors directly in the brain using in vivo
models. Inhibitors can be added directly to the feed media to see direct effects
on cortex. In whole animal models, inhibitors are either added to the blood
stream and may or may not cross the blood brain barrier or by direct cannulation
into the brain. Direct injection in the brain requires surgery with general
anesthetic and the drug can affect additional regions of the brain in close
proximity. Additional of these inhibitors to the cortical explants allows us to see
how these receptors are important by blocking them in a model that maintains
the neuron/glial relationship without influence from other brain regions.
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Previous studies have used sex steroid hormone receptor inhibitors in
explants to evaluate their importance after injury. For example, addition of the
nonspecific ER antagonist (ICI 182,780) blocked the neuroprotective effects of
E2 following injury (Wise, Dubal et al. 2001). ICI blocks both ER! and ER",
therefore these studies did not differentiate the roles of one receptor versus the
other. In another study, addition of 17!-estradiol, an isomer of 17"-estradiol (E2)
that does not bind well to the estrogen receptors, did not reduce cell death (Wise,
Dubal et al. 2001). E2 was also shown to be protective when ER!, compared to
vector DNA, was transfected into PC12 cells (Gollapudi and Oblinger 1999;
Gollapudi and Oblinger 1999). Interestingly, these studies did not look
specifically at each sex steroid receptor individually to decipher their role
separately in E2 mediated protection. While these studies do indicate a role for
sex steroid receptors, they did not evaluate each receptor independently to
determine their role in E2 mediated protection and ischemic induced cell death.
The initial goal of these studies was to determine which receptor is
necessary for the attenuation of cell death in female explants at 24 hours.
Because there was no effect of E2 on cell death in the males or at any other time
point in the females, the secondary goal was to determine if the presence of each
receptor may actually inhibit the ability of E2 to be protective. To accomplish
these goals, I evaluated cell death by measuring propidium iodide uptake and
evaluating changes in sex steroid hormone receptors following treatment with
2DG/KCN in both female and male cortical explants separately. Sex steroid
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hormone receptor antagonists were added either before or after treatment with
2DG/KCN to see how they influence cell death cause by ischemic injury.

Methods
Inhibitors

Cortical explants were isolated from postnatal day 3 (PND 3) female or
male rat pups and grown in culture with media containing either 17 !-estradiol
(E2) (1 nM in 0.01% EtOH) or EtOH (0.01%) vehicle. Antagonists were either
added 24 hours prior to injury or 6 hours post injury. The inhibitors used are listed
below:
1. ER alpha antagonist, MPP dihydrochloride (1,3-Bis(4-hydroxyphenyl)-4methyl-5 -[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride)
(1991, Tocris, Minneapolis, MN) was made up in EtOH to a stock
concentration of 100 mM and added into feed media to a final
concentration of 1 uM (previously published optimized in vitro
concentration) (Harrington, Sheng et al. 2003; Ben-Jonathan, Chen et al.
2009). MPP Dihydrochloride is a selective silent antagonist at the ER!
receptor with more than 200 fold selectivity for ER! than ER". A silent
antagonist is a competitive receptor antagonist that doesn’t intrinsically
activate the receptor.
2. ER beta antagonist, PHTPP (4-[2-Phenyl-5,7-bis (trifluoromethyl )
pyrazolo[1,5-a]pyrimidin-3-yl]phenol) (2662 Tocris, Minneapolis, MN), was
made up in EtOH to a stock concentration of 100 mM and added into feed
media to a final concentration of 1 uM (previously published optimized in
!
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vitro concentration) (Ben-Jonathan, Chen et al. 2009). PHTPP is a
selective ER! receptor antagonist with more than 36 fold selectivity for
ER! than ER".
3. AR antagonist, Flutamide (2-Methyl-N- (4-nitro-3-[trifluoromet hyl]phenyl)
propanamide) (4094 Tocris, Minneapolis, MN), was made up in EtOH to a
stock concentration of 100 mM and added into feed media to a final
concentration of 100 nM. Flutamide is a selective anti-androgenic
antagonist for AR.

Pre-treatment studies
For pre-treatment, on the 6th day in culture (24 hours before injury), 1 uM
antagonist was added into the feed media that contained vehicle (EtOH) or E2.
24 hours later the feed media with or without the antagonist was removed and
explants were injured using 1 mM 2-DG and 0.5 mM KCN for 2 hours in BME
(injury) or BME (control). Feed media with or without the antagonist and with or
without E2 was replaced after the two hours and cell death was analyzed using
propidium iodide (PI) 24 hours after the addition of 2DG/KCN.

Post-treatment studies
For post-treatment of the antagonist, on the 7th day in culture, explants
maintained in the presence of EtOH or E2 were injured using 1 mM 2-DG and 0.5
mM KCN for 2 hours in BME (injury) or BME (control). 6 hours after injury, 1 nM
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or 1 uM of the antagonist was added into the feed media that contained EtOH or
E2. 24 hours following the injury cell death was analyzed using PI.
At each treatment (EtOH/E2), inhibitor (vehicle/drug) and injury (non
injured/ 2DG/KCN treated) condition at least 3 explants were processed per well.
For example, 1 well of at least 3 females explants that were grown in EtOH
treated media and pretreated with an antagonist for 24 hours before injury were
processed 24 hours after injury with propidium iodide to determine the extent of
cell death. Each explant in the well was considered an N of 1. This was
repeated at least 3 times with a new set of litters each time. Explants were
visualized using a fluorescent microscope. Pictures of explants at 20X were
captured using an image capture program, SPOT Advanced. Red (dead) cells
were then counted using an NIH program, Image J. Pictures were coded and
analyzed blindly. Injured explants were compared back to the corresponding
vehicle treated non-injury for each hour and sex.

Statistics
For the cell death studies, 3 litters were used to dissect female and male
cortical explants. Cortical explants were taken from female rat pups at postnatal
day 3 (PND 3) and maintained in culture media containing vehicle or estrogen.
Explants were either pre-treated or post-treated with inhibitors (described above)
then each inhibitor scenario was split into non-injured and 2DG/KCN treated
groups. At each treatment (EtOH/E2), drug (vehicle/antagonist) and injury (noninjured/ 2DG/KCN treated) condition at least 3 explants were processed per well.
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For example, 1 well of at least 3 females explants that were grown in EtOH
treated media and inhibited for 24 hours before injury were processed 24 hours
after injury with PI to determine the extent of cell death. Each explant in the well
was considered an N of 1. This was repeated at least 3 times with a new set of
litters each time.
Since we were interested if antagonizing a specific sex steroid receptor
had an effect on cell death, we evaluated the effect of each antagonist on cortical
explants injured with 2DG/KCN and pre-treated with E2. A three-way ANOVA
comparing the factors “drug” (vehicle/ antagonist), “treatment” (EtOH/ E2) and
“injury” (non injured/ 2DG/KCN) were evaluated for each receptor antagonist
scenario. If a significant interaction between drug, treatment or injury was
detected, Student Newman-Keuls post hoc test were performed. All three
inhibitors have a 24 hour pre-treatment at 1uM and a 6 hour post-treatment at 1
nM and 1 uM.
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Results
Overview
Drugs were either added as a pre-treatment as described in previous
studies or as a post-treatment. Because we did not see the level of cell death we
anticipated, we were concerned that the drug in the culture media before injury
may be influencing the ability of 2DG/KCN to induce cell death. To eliminate this
problem, we included two additional paradigms where inhibitor drugs were added
following injury. First, I added inhibitor 6 hours post-injury to determine if this
would interfere with the cell death in response to 2DG/KCN treatment. We also
added a lower concentration of the antagonists at 6 hours post-injury to
determine if the inhibitor’s effects were dose dependent.
Drugs were either added as a pre-treatment as described in previous
studies or as a post-treatment. Because we did not see the level of cell death we
anticipated, we were concerned that the drug in the culture media before injury
may be influencing the ability of 2DG/KCN to induce cell death. To eliminate this
problem, we included two additional paradigms where inhibitor drugs were
actually added following injury. First, I added inhibitor 6 hours post injury to
determine if this would interfere with the cell death in response to 2DG/KCN
treatment. We also added a lower concentration of the antagonists at 6 hours
post-injury to determine if the drug concentration alone was affecting cell death.
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Part 1: Role of each sex steroid hormone receptor in FEMALE explants.

Does inhibiting ER! influence cell death in female cortical explants?
MPP is a high affinity specific ER! antagonist that inhibits at the receptor.
We choose this inhibitor over previously published inhibitors because this
particular antagonist has a selectivity of 200 fold more affinity for ER! over ER".
ICI 182,780 was used in previous studies (Wise, Dubal et al. 2001), but this
inhibitor affects both ER! and ER", which would not allow me to decipher which
receptor is specifically involved.

MPP Pre-treatment
To determine the effects of the ER! antagonist, MPP, and the presence of
E2 on cell death following injury with 2DG/KCN in female cortical explants, a
three-way ANOVA was performed comparing the factors “drug” (vehicle and
MPP), “injury” (non-injured and 2DG/KCN treated) and “treatment” (EtOH and
E2). This test revealed no main effects of drug, injury or E2 treatment, but did
reveal an interaction between drug and injury (p<0.0001, F=16.642, df=1,104),
Figure 4.1. Post-hoc t-tests revealed three significant differences. First,
2DG/KCN produced a significant increase in cell death in the vehicle (no drug)
(p<0.0001; compared to non-injured vehicle (no drug) group). Next, MPP pretreatment increased cell death in the non-injured group (p<0.05; compared to the
non-injured vehicle group). Lastly, MPP pre-treatment significantly decreased cell
death in the 2DG/KCN injured explants (p<0.005; compared to the vehicle (no
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drug) 2DG/KCN injured explants). This decrease in cell death indicates that when
2DG/KCN is applied in the presence of MPP that this drug significantly protects
female cortical explants from the 2DG/KCN induced injury. Interestingly, when
female cortical explants were pre-treated with MPP, 2DG/KCN did not produce a
significant injury (p>0.05; compared to MPP non-injured). To summarize these
results, 2DG/KCN caused a significant injury in the vehicle (no drug) group, and
MPP pretreatment increased cell death in uninjured cultures but protected
against cell death in cultures subjected to 2DG/KCN injury.
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Ratio of Cell Death To Vehicle Non Injured
Propidium Iodide Uptake (Image J)
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Figure 4.1. Cell death in female cortical explants after pre-treatment with
MPP, an ER! antagonist. Overall, 2DG/KCN increased cell death in the vehicle
(no drug) explants. MPP pre-treatment significantly increased cell death in the
non-injured explants. Asterisks indicate a significant increase in cell death from
the vehicle (no drug) non-injured group. Interestingly, in the 2DG/KCN injured
explants, MPP pre-treatment decreased cell death compared to vehicle (no drug)
explants. The letter “a” on graph indicates a decrease in cell death from vehicle
2DG/KCN injured explants. Asterisks (*) and the letter “a” on the graph indicate
significant differences, p< 0.05. Error bars represent SEM.
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MPP Post-treatment
2DG/KCN did not produce a significant injury when the female cortical
explants were pre-treated with MPP. To determine if MPP, the ER! antagonist,
was affecting 2DG/KCN’s ability to block oxidative phosphorylation and glycolysis
(ischemic injury), MPP was added after the 2DG/KCN injury at two different
paradigms (described in methods).

6 hour post-treatment of 1 uM MPP Dihydrochloride
The same concentration of MPP (1 uM) used for the 24 hour pre-treatment
was added 6 hours following the 2DG/KCN injury. A three-way ANOVA
comparing the factors drug, injury and treatment revealed a significant main
effect of injury (p=0.0006, F=12.522, df=1,105) and an interaction of drug and
injury (p=0.0328, F=4.680, df=1,105). Post-hoc t-test revealed three significant
differences, Figure 4.2. First, 2DG/KCN increased cell death in the vehicle (no
drug) group (p <0.001; compared to the non-injured vehicle (no drug) group and
p<0.05; compared to the non-injured MPP group). Lastly, MPP treatment
significantly decreased cell death in the 2DG/KCN injured explants (p<0.05;
compared to vehicle (no drug) 2DG/KCN injured explants). This decrease in cell
death indicates that post-treatment with MPP protects female cortical explants
from an increase in cell death due to 2DG/KCN. Interestingly, 2DG/KCN did not
produce a significant injury within the MPP group (p>0.05; compared to MPP
non-injured explants). To summarize these results, 2DG/KCN causes a
significant injury in the vehicle (no drug) group compared to the vehicle no injury
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and to the MPP no injury. A significant 2DG/KCN induced injury could not be
reached with in the MPP group at 1 um. A lower concentration of MPP was also
applied post-treatment to see if the MPP concentration was too high.
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Figure 4.2. Cell death in female cortical explants after post-treatment with 1
uM MPP. Overall, 2DG/KCN increased cell death in the vehicle (no drug)
explants. Asterisks indicate a significant increase in cell death from the vehicle
(no drug) non-injured group. Interestingly, MPP post-treatment decreased cell
death from the vehicle 2DG/KCN injured. The letter “a” indicates less cell death
as compared to the 2DG/KCN vehicle. Asterisks (*) and the letter “a” on the
graph indicate significant differences, p< 0.05. Error bars represent SEM.
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6-hour post-treatment with 1 nM MPP
A 1000 fold weaker concentration (1 nM) of MPP than was previous used
was added 6 hours after injury with 2DG/KCN to see if 2DG/KCN can induce
significant injury in the presence of 1 nM MPP. A three-way ANOVA comparing
the factors drug, injury and treatment was conducted and revealed a significant
main effect of injury (p<0.0001, F=16.369, df=1, 105), but no main effect of drug
or treatment and no interactions, Figure 4.3. These data indicate that 2DG/KCN
significantly increased cell death regardless if the explants were vehicle (no drug)
or 1 nM MPP treated 6 hours after injury.
Note: p value for an interaction between drug and treatment was 0.054,
which is not significant, but extremely close. This indicates a trend that in the
vehicle (no drug) group, E2 had less cell death than in the absence of E2.
However, the MPP post-treatment group had a trend for an increase in cell death
in the presence of E2.
These results did not confirm our initial hypothesis that blocking ER!
activity, either with a 24 hour pretreatment or a 6 hour post-treatment relative to
2DG/KCN induced injury, would remove the E2-mediated protection seen in
female cortical explants.
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Figure 4.3. Cell death in female cortical explants after post-treatment with
ER! inhibitor 1 nM MPP. Overall, 2DG/KCN increased cell death in both the
vehicle and MPP treated groups. Error bars represent SEM.
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Does inhibiting ER! influence cell death in female cortical explants?
PHTPP is a selective ER! receptor antagonist. We choose this inhibitor
over previously published inhibitors because this particular antagonist has a 36
fold more affinity for ER! than ER". ICI was used in previous studies (Wise,
Dubal et al. 2001), but this inhibitor affects both ER" and ER! which would not
allow me to decipher which receptor is specifically involved.

PHTPP Pre-treatment
To determine the effects of the ER! antagonist, PHTPP, and the presence
of E2 on cell death following injury with 2DG/KCN in female cortical explants, a
three-way ANOVA comparing the factors “drug” (Vehicle and PHTPP), “injury”
(non-injured and 2DG/KCN treated) and “treatment” (EtOH and E2) was
performed. This test revealed a significant main effect of injury (p=0.0148,
F=6.127, df=1,110) and an interaction of drug and injury (p=0.0006, F=12.489,
df=1,110). Post-hoc t-tests revealed that 2DG/KCN significantly increased cell
death in the vehicle (no drug) group (p<0.05; compared to vehicle (no drug) noninjured and p<0.05; compared to PHTPP non-injured). PHTPP decreased cell
death in the 2DG/KCN group (p<0.05; compared to vehicle (no drug) 2DG/KCN
injured). This indicates that pre-treatment with PHTPP protects female cortical
explants from cell death induced by 2DG/KCN. Interestingly, 2DG/KCN did not
induce a significant injury within the PHTPP group (p<0.05; compared to PHTPP
non-injured). To summarize these results, 2DG/KCN caused a significant injury
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in the vehicle (no drug) group PHTPP pre-treatment protected against cell death
in the 2DG/KCN injured cultures.
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Propidium Iodide Uptake (Image J)

5

Cell Death in Female Cortical Explants

EtOH

ER beta Antagonist

*

4

E2

a

3

a

2

1

0

Non Injury

2DG/KCN

Vehicle

Non Injury

2DG/KCN

24 Hour Pre-Treatment
1 uM PHTPP
(ER beta antagonist)

Figure 4.4. Cell death in female cortical explants after pre-treatment with
PHTPP, an ER! antagonist. Overall, 2DG/KCN increased cell death in the
vehicle (no drug) explants. Asterisks indicate a significant increase in cell death
from the vehicle (no drug) non-injured group. Interestingly, PHTPP pre-treatment
decreased cell death from the vehicle 2DG/KCN injured. The letter “a” indicates
less cell death as compared to the 2DG/KCN vehicle. Asterisks (*) and the letter
“a” on the graph indicate significant differences, p< 0.05. Error bars represent
SEM.
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6 hour post-treatment of 1 uM PHTPP
The same concentration of PHTPP (1 uM) use for the 24 hour pretreatment was added 6 hours following the 2DG/KCN injury. A three-way
ANOVA comparing the factors “drug”, “injury” and “E2 treatment” was conducted
and revealed a significant main effect of injury (p=0.004, F=8.66, df=1,102), an
interaction of drug and injury (p=0.0112, F=6.66, df=1,102) and an interaction of
injury and treatment (p=0.050, F=5.17, df=1,102).
Post-hoc tests between drug and injury revealed 3 interactions, Figure 4.5.
First, 2DG/KCN significantly increased cell death in the vehicle (no drug) group
(p<0.001; compared to vehicle (no drug) non-injured and p<0.05; compared to
the PHTPP non-injured). PHTPP post-treatment significantly reduced cell death
in the 2DG/KCN injured explants (p<0.05; compared to the vehicle (no drug)
2DG/KCN injured). Interestingly, 2DG/KCN did not induce a significant injury
within the PHTPP. To summarize these results 2DG/KCN caused a significant
injury in the vehicle (no drug) group and PHTPP significantly reduced cell death
from the 2DG/KCN vehicle (no drug).
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Figure 4.5. Cell death in female cortical explants after post-treatment with 1
uM PHTPP, an ER! antagonist, illustrating injury and drug effects. Overall,
2DG/KCN increased cell death in the vehicle (no drug) explants. Asterisks
indicate a significant increase in cell death from the vehicle (no drug) non-injured
group. Interestingly, PHTPP post-treatment, regardless of injury with 2DG/KCN,
decreased cell death from the vehicle 2DG/KCN injured. The letter “a” indicates
less cell death as compared to the 2DG/KCN vehicle. Asterisks (*) and the letter
“a” on the graph indicate significant differences, p< 0.05. Error bars represent
SEM.
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Post-hoc tests between injury and treatment revealed 4 interactions, Figure 4.6.
First, 2DG/KCN significantly increased cell death in the EtOH group (p<0.05;
compared to EtOH non-injured and p<0.05; compared to E2 non-injured). E2
pre-treatment significantly increased cell death in the non-injured explants
(p<0.05; compared to the EtOH non-injured). 2DG/KCN significantly increased
cell death in the E2 pre-treated group (p<0.05; compared to EtOH non-injured).
Interestingly, there was no additional cell death with 2DG/KCN injury in the E2
pre-treated explants above E2 non-injured.
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Figure 4.6. Cell death in female cortical explants after post-treatment with 1
uM PHTPP, an ER! antagonist, illustrating injury and E2 treatment effects.
Overall, 2DG/KCN increased cell death in the EtOH group. E2 pre-treatment
increased cell death from the EtOH group. Asterisks indicated a significant
increase in cell death from the EtOH (vehicle) non-injured group. E2 pre-treated
non-injured explants had significantly lower cell death than the 2DG/KCN EtOH
explants (indicated by the letter “a” on graph). Asterisks (*) and the letter “a” on
the graph indicate significant differences, p< 0.05. Error bars represent SEM.
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6 hour post-treatment of 1 nM PHTPP
A 1000 fold weaker concentration (1 nM) of PHTPP than was previous
used in the post-treatment experiment was added 6 hours after 2DG/KCN injury
to see if 2DG/KCN can induce significant injury. A three-way ANOVA comparing
the factors “drug”, “injury” and “treatment” revealed a significant main effect of
injury (p<0.0005, F=12.77, df=1, 103), but no main effect of drug or treatment
and no interactions, Figure 4.7. These data indicate that 2DG/KCN significantly
increased cell death regardless if the explants were vehicle (no drug) or 1 nM
PHTPP treated 6 hours after injury and regardless of whether explants were
pretreated with E2.
These results did not confirm our initial hypothesis that blocking ER!
activity, either with a 24 hour pre-treatment or a 6 hour post-treatment relative to
2DG/KCN injury, would remove the E2-mediated protection seen in female
cortical explants.
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Figure 4.7. Cell death in female cortical explants after post-treatment with 1
nM ER! antagonist PHTPP. Overall, 2DG/KCN increased cell death in both the
vehicle (no injury) and the 1 nM PHTPP groups. Error bars represent SEM.
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Does Flutamide influence cell death in female cortical explants?
Flutamide is a selective non-steroidal antiandrogen antagonist for the androgen
receptor.
Flutamide Pre-treatment
To determine the effects of the AR antagonist, Flutamide, and the
presence of E2 on 2DG/KCN induced cell death in female cortical explants, a
three-way ANOVA comparing the factors “drug” (vehicle and Flutamide), “injury”
(non-injured and 2DG/KCN injured) and “treatment” (EtOH and E2) was
conducted. This test revealed a main effect of injury (p=0.0012, F=10.904,
df=1,134), an interaction with drug and injury (p<0.0001, F=23.107, df=1,134)
and an interaction with injury and treatment (p=0.0430, F=4.176, df=1,134).
Post-hoc t-tests looking at the interaction between drug and injury (Figure
4.8) revealed 2DG/KCN significant increased cell death in the vehicle group
(p<0.001; compared to the vehicle non-injured and p<0.001; compared to
PHTPP non-injured). Flutamide pretreatment caused an increase in cell death
among the non-injured (p<0.05; compared to EtOH non-injured). Pre-treatment
with Flutamide decrease cell death among the 2DG/KCN injured (p<0.001;
compared to vehicle 2DG/KCN injured). Interestingly, 2DG/KCN did not cause a
significant injury when Flutamide was present (p>0.05; compared to Flutamide
non-injured).
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Figure 4.8. Cell death in female cortical explants after pre-treatment with 1
uM AR antagonist, Flutamide, illustrating injury and drug effects. Overall,
2DG/KCN increased cell death in the vehicle group. Pre-treatment with
Flutamide increased cell death in the non-injured group. Asterisks indicate a
significant increase in cell death from the vehicle (no drug) non-injured group.
Pre-treatment with Flutamide significantly decreased cell death from the vehicle
(no drug) 2DG/KCN injured. The letter “a” indicates less cell death as compared
to the 2DG/KCN vehicle. Asterisks (*) and the letter “a” on the graph indicate
significant differences, p< 0.05. Error bars represent SEM.
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Post hoc t-tests comparing injury and treatment revealed 3 significant
effects, Figure 4.9. 2DG/KCN significantly increased cell death in the EtOH group
(p<0.001, compared to EtOH non-injured and p<0.05, compared to E2 noninjured). E2 pre-treatment significantly decreased cell death (p<0.05; compared
to EtOH 2DG/KCN injured). Interestingly, significantly injury could not be
reached with 2DG/KCN within the pre-treatment Flutamide group.
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Figure 4.9. Cell death in female cortical explants after pre-treatment with 1
uM AR antagonist, Flutamide, illustrating injury and treatment effects.
Overall, 2DG/KCN significant increased cell death in the EtOH group. Asterisks
on the graph indicate significant increases from EtOH non-injured. Pre-treatment
with E2 regardless of injury with 2DG/KCN significantly reduced cell death from
the EtOH 2DG/KCN induced injury (indicated by the letter “a” on graph).
Asterisks (*) and the letter “a” on the graph indicate significant differences, p<
0.05. Error bars represent SEM.
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Flutamide Post-treatment
To determine if the antagonist was affecting 2DG/KCN’s ability to block
oxidative phosphorylation and glycolysis (ischemic injury), we added the inhibitor
after the injury in two different paradigms (described in methods sections)

6 hour post-treatment of 1 uM Flutamide
A three-way ANOVA comparing the factors “drug”, “injury” and “treatment”
revealed an interaction of drug and injury (p=0.0007, F=12.218, df=1,108). The
post-hoc t-test revealed 3 interactions, Figure 4.10. First, 2DG/KCN significantly
increased cell death in the vehicle group (p<0.05; compared to vehicle noninjured). Post-treatment with Flutamide increased cell death in the non-injured
explants (p<0.05; compared to vehicle non-injured). However, post-treatment
with Flutamide in the presence of 2DG/KCN decreased cell death (p<0.05;
compared to vehicle 2DG/KCN). Interestingly, 2DG/KCN did not produce a
significant injury within the Flutamide post-treated group (p>0.05; compared to
Flutamide non-injured).
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Figure 4.10. Cell death in female cortical explants after post-treatment with
1 uM AR antagonist, Flutamide. Overall, 2DG/KCN increased cell death in the
vehicle group. Post-treatment with Flutamide increased cell death in the noninjured explants. Asterisks indicate a significant increase in cell death from the
vehicle (no drug) non-injured group. Interestingly, there was a decrease in cell
death with the post-treatment of Flutamide in the 2DG/KCN-injured explants. The
letter “a” on the graph indicates decreases in cell death from vehicle 2DG/KCN
injured. Asterisks (*) and the letter “a” on the graph indicate significant
differences, p< 0.05. Error bars represent SEM.
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6-hour post-treatment with 1 nM Flutamide
Because I wanted to see not only how adding a lower concentration, 1 nM,
of Flutamide after injury affected cell death, but also how E2 pre-treatment and
2DG/KCN induced injury affected cell death a three-way ANOVA comparing the
factors “drug”, “injury” and “treatment” was conducted. This test revealed a
significant main effect of injury (p=0.0047, F=8.323, df=1, 115), an interaction
with drug and injury (p=0.0003, F=14.039, df=1,115) and an interaction with all
three factors (drug, treatment and injury).
The post hoc t-tests evaluating the interaction between injury and drug
(Figure 4.11) revealed 2DG/KCN significant increased cell death in the vehicle
group (p<0.001; compared to vehicle non-injured and p<0.05; compared to
Flutamide non-injured). Flutamide post-treatment decreased cell death in the
2DG/KCN injured explants (p<0.001; compared to vehicle 2DG/KCN injured).
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Figure 4.11. Cell death in female cortical explants after post-treatment with
1 nM AR antagonist, Flutamide, illustrating injury and drug effects. Overall,
2DG/KCN increased cell death in the vehicle group. Asterisks indicate a
significant increase in cell death from the vehicle (no drug) non-injured group.
Interestingly, there was a decrease in cell death with the post-treatment of
Flutamide in both the non-injured and the 2DG/KCN injured explants. The letter
“a” indicates less cell death as compared to the 2DG/KCN vehicle. Asterisks (*)
and the letter “a” on the graph indicate significant differences, p< 0.05. Error bars
represent SEM.
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The post hoc to evaluate the interaction between drug, treatment and
injury revealed 7 interactions (Figure 4.12). 2DG/KCN increased cell death in the
EtOH vehicle (no drug) group compared to all non-injured groups (p<0.001;
compared to non-injured EtOH vehicle (no drug), p<0.001; compared to noninjured E2 vehicle (no drug), p<0.05; compared to Flutamide EtOH non-injured,
and p<0.05; compared to Flutamide E2 non-injured). E2 pre-treatment and
Flutamide post-treatment decreased cell death from the vehicle 2DG/KCN injured
explants (p<0.05, compared to the EtOH vehicle (no drug) 2DG/KCN injured). In
summary, 2DG/KCN induced significant cell death in vehicle/EtOH (control)
cultures. This cell death was reduced by E2 pre-treatment, but protection was
not affect by Flutamide. EtOH vehicle (no drug) 2DG/KCN injured explants had
significantly more cell death than all of the other experimental groups. In the
presence of Flutamide, 2DG/KCN does not cause significant injury.
These results did not confirm our initial hypothesis that blocking AR
activity, either with a 24 hour pre-treatment or a 6 hour post-treatment relative to
2DG/KCN injury, would remove the E2-mediated protection seen in female
cortical explants. An AR antagonist was included because AR mRNA expression
increased in the cortex and in cortical explants across development. AR along
with ER! mRNA expression was high at 22 DIC suggesting a role for these
receptors in the adult cortex.
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Figure 4.12. Cell death in female cortical explants after post-treatment with
AR inhibitor Flutamide, illustrating drug, injury and treatment effects.
Overall, 2DG/KCN increased cell death in the EtOH vehicle non-injured
compared to both EtOH and E2 non-injured vehicle explants. Asterisks
indicated a significant increase in cell death from all non-injured group. E2 pretreatment or Flutamide post-treatment significantly reduced cell death from EtOH
vehicle (no drug) 2DG/KCN injured explants. The letter “a” indicates a decrease
from EtOH vehicle (no drug) 2DG/KCN injured. Asterisks (*) and the letter “a” on
the graph indicate significant differences, p< 0.05. Error bars represent SEM.
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Part 2. How does antagonizing sex steroid hormone receptors affect cell
death in MALE cortical explants following injury?
Male cortical explants were also evaluated with each inhibitor scenario.
Initially we evaluated the sex steroid hormone antagonist in female cortical
explants in hopes of removing the E2 mediated protection. However, in the
female cortical explants, when we inhibited ER!, ER" or AR there was a further
reduction in cell death in both EtOH and E2-treated explants. This led us to
believe that the sex steroid hormone levels were involved in the cell death
induced by 2DG/KCN and by antagonizing ER!, ER" or AR we could attenuate
cell death following a 2DG/KCN induce injury in a E2 treatment independent
pathway. In chapter one we evaluated mRNA levels of these receptors, ER!,
ER" or AR, across time in culture and did not see any sex difference in
expression. However, in chapter two we evaluated these receptors following
injury and discovered specific sex response following injury in ER! and AR
mRNA expression. Even though only female explants had a significant increase
in mRNA following injury does not remove the theory that these sex steroid
hormones are having an effect in male explants also. The protein levels of these
receptors directly correlate to the activity level of these receptors. Therefore,
male cortical explants were also evaluated in each inhibitor scenario to determine
what effect ER!, ER" or AR had following injury.
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Does inhibiting ER! influence cell death in MALE cortical explants?
MPP Dihydrochloride (MPP) is a high affinity specific ER! antagonist that
inhibits at the receptor.
MPP Pre-treatment
To determine the effects of the ER! antagonist, MPP, on 2DG/KCN
induced cell death in E2 treated male cortical explants, a three-way ANOVA
comparing the factors “drug” (vehicle and MPP), “injury” (non-injured and
2DG/KCN treated) and “treatment” (EtOH and E2). This test revealed a main
effect injury (p=0.0023, F=9.676, df=1,125), but no main effect of drug and no
interactions, Figure 4.13. This indicated that 2DG/KCN caused significant injury,
which was not dependent on pretreatment with MPP or E2. Interestingly, male,
unlike female, cortical explants did not have an increase in cell death in the noninjured explants with the pretreatment of MPP.
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Figure 4.13. Cell death in male cortical explants after pre-treatment with
MPP, ER! antagonist. Overall, 2DG/KCN caused significant injury, which was
not dependent on pretreatment with MPP or E2. Error bars represent SEM.

!

155

6 hour post-treatment of 1 uM MPP Dihydrochloride
The same concentration of MPP (1 uM) that was used for the 24 hour pretreatment was added 6 hours following injury with 2DG/KCN. A three-way
ANOVA comparing the factors drug, injury and treatment was conducted and
revealed a significant main effect of injury (p=0.0220, F=5.375, df=1,126) and an
interaction of drug and injury (p=0.0107, F=6.721, df=1,126). The post hoc t-test
revealed that 2DG/KCN caused significant injury in the vehicle (no drug) group
(p<0.05; compared to vehicle non-injured). 2DG/KCN did not cause significant
injury when the male cortical explants were post-treated with MPP.
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Figure 4.13. Cell death in male cortical explants after post-treatment with 1
uM MPP, ER! antagonist. Overall, 2DG/KCN increased cell death in the
vehicle (no drug) group. Asterisks indicated a significant increase in cell death
from the vehicle (no drug) non-injured group. Asterisks (*) on the graph indicate
significant differences, p< 0.05. Error bars represent SEM.
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6-hour post-treatment with 1 nM MPP
1000 fold weaker concentration (1 nM) of MPP than was previous used (1
uM) in the post-treatment experiment of MPP was added 6 hours after 2DG/KCN
injury to see if 2DG/KCN can induce significant cell death in the presence of
MPP. A three-way ANOVA comparing the factors “drug”, “injury” and “treatment”
were conducted. This test also revealed a main effect injury (p=0.0008,
F=11.675, df=1,128), but no main effects of drug or treatment and no
interactions. This indicated that 2DG/KCN induced significant injury regardless
of E2 pretreatment or application of 1 nM MPP after injury. This is interesting
because 2DG/KCN produced significant cell death when explants were
pretreated with 1 uM MPP, but not when they were post-treated with 1 uM MPP.
The weaker concentration (1 nM) of MPP that was applied post-treatment no
longer blocked 2DG/KCN-induced injury.
In summary, 2DG/KCN induced significant injury, from vehicle (no drug)
non-injured, when 1 um MPP was applied 24 hours before injury or 1 nM MPP
was applied 6 hours following injury. However, in these scenario’s 2DG/KCN did
not induce a significant injury within the MPP group, compared to MPP noninjured. This indicates that MPP increased cell death in the non-injured MPP
group and removed 2DG/KCN’s ability to cause significant cell death above the
MPP non-injured group, although the MPP 2DG/KCN injury was significantly
different from the vehicle non-injured. Interestingly, when 1 uM MPP was added
6 hours following injury, 2DG/KCN did not induce a significant injury. These
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results did confirm our hypothesis for male cortical explants that blocking ER!
activity would alter the injury induced by 2DG/KCN.
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Figure 4.14. Cell death in male cortical explants after post-treatment with 1
nM MPP, ER! inhibitor. Overall, 2DG/KCN increased cell death in the vehicle
(no drug) and in the MPP pre-treatment group. Error bars represent SEM.
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24 hour pre-treatment of 1 uM PHTPP
To determine the effects of the ER! antagonist, PHTPP, on cell death in
male cortical explants, a three-way ANOVA comparing the factors “drug” (Vehicle
and PHTPP), “injury” (non injured and 2DG/KCN treated) and “treatment” (EtOH
and E2) was conducted. This test revealed a main effect of injury (p=0.0101,
F=6.765, df=1,127) and an interaction between drug and injury (p=0.0193,
F=5.616, df=1,127. Post-hoc t-tests revealed 2DG/KCN increased cell death in
the vehicle group (p<0.05; compared to vehicle non-injured). Pre-treatment with
PHTPP decreased cell death in the 2DG/KCN group (p<0.05; compared to
vehicle 2DG/KCN injured). Pre-treatment with PHTPP also prevented 2DG/KCN
from inducing significant injury (p>0.05; compared to PHTPP non-injured).
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Figure 4.15. Cell death in male cortical explants after pre-treatment with
PHTPP, an ER! antagonist. Overall, 2DG/KCN increased cell death in the
vehicle (no drug). Asterisks indicated a significant increase in cell death from the
vehicle (no drug) non-injured group. Interestingly, there was a decrease in cell
death with the pre-treatment of PHTPP in the 2DG/KCN injured explants. The
letter “a” on graph indicates a significant decrease in cell death from the vehicle
2DG/KCN. Asterisks (*) and the letter “a” on the graph indicate significant
differences, p< 0.05. Error bars represent SEM.
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6 hour post-treatment of 1 uM PHTPP
The same concentration of PHTPP (1 uM) used for the 24 hour pretreatment was added 6 hours following injury with 2DG/KCN. A three-way
ANOVA comparing the factors “drug”, “injury” and “treatment” was conducted.
This test revealed a significant main effect of injury (p=0.020, F=5.549, df=1, 125)
and an interaction with drug and injury (p=0.006, F=7.768, df=1,125). Post-hoc ttests revealed that 2DG/KCN induced significant injury in the vehicle group
(p<0.001; compared to vehicle non-injured). PHTPP post-treatment increased
cell death in the non-injured (p<0.05; compared to vehicle (no drug) non-injured)
and in the 2DG/KCN injured (p<0.05; compared to vehicle (no drug) non-injured).
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Figure 4.16. Cell death in male cortical explants after post-treatment with 1
uM PHTPP, an ER! antagonist. Overall, 2DG/KCN increased cell death in the
vehicle (no drug) and in PHTPP compared to vehicle non-injured. Post-treatment
with PHTPP also increased cell death in the non-injured group. Asterisks
indicated a significant increase in cell death from the vehicle (no drug) noninjured group, p< 0.05. Error bars represent SEM.
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6 hour post-treatment of 1 nM PHTPP
A three-way ANOVA comparing the factors “drug”, “injury” and “treatment”
was conducted and revealed a significant main effect of injury (p=0.0135,
F=6.277, df=1, 120) and an interaction with drug and injury (p=0.0061, F=7.769,
df=1,125). Post-hoc t-tests revealed that 2DG/KCN induced a significant injury in
the vehicle and PHTPP group (p<0.001; compared to vehicle non-injured).
PHTPP caused significant cell death in the non-injured (p<0.05; compared to
vehicle non-injured). This is interesting because PHTPP post-treatment
increased cell death in the non-injured, but PHTPP pre-treatment did not
increase cell death in the non-injured. These results did confirm our hypothesis
for male cortical explants that blocking ER! activity 24 hours before 2DG/KN
would alter the cell death induced by 2DG/KCN. However, post-treatment with
PHTPP did not confirm our initial hypothesis because cell death was equivalent
to the vehicle (no drug) groups, suggesting blocking ER! post-treatment did not
alter injury with 2DG/KCN.
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Figure 4.17. Cell death in male cortical explants after post-treatment with 1
nM PHTPP, an ER! antagonist. Overall, 2DG/KCN increased cell death in the
vehicle (no drug) and PHTPP groups compared to vehicle non-injured explants.
Post-treatment with PHTPP also increased cell death in the non-injured group.
Asterisks indicated a significant increase in cell death from the vehicle (no drug)
non-injured group, p< 0.05. Error bars represent SEM.
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Does Flutamide influence cell death in male cortical explants?
Flutamide is a selective non-steroidal anti-androgen antagonist for the androgen
receptor.

Flutamide Pre-treatment
To determine the effects of the AR antagonist, Flutamide, and the
presence of E2 on cell death following injury with 2DG/KCN in male cortical
explants, a three-way ANOVA comparing the factors “drug” (Vehicle and
Flutamide), “injury” (non-injured and 2DG/KCN treated) and “treatment” (EtOH
and E2) revealed a main effect of injury (p=0.0029, F=9.226, df=1,129), main
effect of drug (p=0.0031, F=9.085, df=1,129), and an interaction between drug
and injury (p=0.0100, F=6.834, df=1,129). Post-hoc t-tests revealed that
2DG/KCN increased cell death in the vehicle group (p<0.001, compared to
vehicle non-injured and p<0.001; compared to Flutamide non-injured). Flutamide
pre-treatment decreased cell death in the 2DG/KCN group (p<0.001; compared
to vehicle 2DG/KCN). In summary, 2DG/KCN induced injury in the vehicle and
the presence of Flutamide significantly lowered this cell death.
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Figure 4.18. Cell death in male cortical explants after pre-treatment with
Flutamide, an AR inhibitor Flutamide. Overall, 2DG/KCN increased cell death
in the vehicle (no drug). Asterisks indicated a significant increase in cell death
from the vehicle (no drug) non-injured group. Pre-treatment with Flutamide
decreased cell death from the vehicle 2DG/KCN injured. The letter “a” indicates
less cell death as compared to 2DG/KCN vehicle. Asterisks (*) and the letter “a”
on the graph indicate significant differences, p< 0.05. Error bars represent SEM.
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6 hour post-treatment of 1 uM Flutamide
The same concentration of Flutamide (1 uM) used for the 24 hour pretreatment was added 6 hours following injury with 2DG/KCN. A three-way
ANOVA comparing the factors drug, injury and treatment revealed an effect of
injury (p=0.0052, F=8.084, df=1,136), an interaction with drug and injury
(p=0.0024, F=9.590, df=1,136). Post-hoc t-tests revealed 2DG/KCN significantly
increased cell death in the vehicle (p<0.05; compared to vehicle non-injured).
Post-treatment with Flutamide significantly reduced cell death in the 2DG/KCN
group (p<0.05; compared to vehicle 2DG/KCN injured). 2DG/KCN did not induce
significant injury (p>0.05; compared to Flutamide non-injured) when the explants
were treated 6 hours following injury with Flutamide.
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Figure 4.19. Cell death in male cortical explants after post-treatment with 1
uM Flutamide, an AR inhibitor Flutamide. Overall, 2DG/KCN increased cell
death in the vehicle (no drug). Asterisks indicated a significant increase in cell
death from the vehicle (no drug) non-injured group. Post-treatment with
Flutamide reduced cell death in the 2DG/KCN group. The letter “a” indicates a
decrease in cell death from the 2DG/KCN vehicle group. Asterisks (*) and the
letter “a” on the graph indicate significant differences, p< 0.05. Error bars
represent SEM.
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6-hour post-treatment with 1 nM Flutamide
1000 fold weaker concentration (1 nM) of Flutamide than was previous
used (1 uM) in the post-treatment experiment of Flutamide was added 6 hours
after 2DG/KCN injury to see if 2DG/KCN can induce significant cell death in the
presence of Flutamide. A three-way ANOVA comparing the factors “drug”,
“injury” and “treatment” were conducted. This test also revealed a main effect of
injury (p=0.0018, F=10.109, df=1,134), a main effect of drug (p=0.0151, F=6.061,
df=1, 134) and an interaction with drug and injury (p=0.0095, F=6.918, df=1,134).
Post-hoc t-tests revealed 2DG/KCN significantly increased cell death in the
vehicle (p<0.05; compared to vehicle non-injured).
Post-treatment with Flutamide significantly reduced cell death (p<0.05;
compared to vehicle 2DG/KCN injured). 2DG/KCN did not induce significant
injury (p>0.05; compared to Flutamide non-injured) when the explants were
treated 6 hours following injury with Flutamide. These results did confirm our
hypothesis for male cortical explants that blocking AR activity would alter the
injury induced by 2DG/KCN.
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Figure 4.20. Cell death in male cortical explants after post-treatment with 1
nM Flutamide, an AR inhibitor Flutamide. Overall, 2DG/KCN increased cell
death in the vehicle (no drug). Asterisks indicated a significant increase in cell
death from the vehicle (no drug) non-injured group. Post-treatment with
Flutamide decreased cell death from the vehicle 2DG/KCN injured. The letter “a”
indicates less cell death as compared to the 2DG/KCN vehicle. Asterisks (*) and
the letter “a” on the graph indicate significant differences, p< 0.05. Error bars
represent SEM.
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Discussion
Here, we describe the role of sex steroid hormone receptors in female and
male cortical explants treated with 2DG/KCN. Sex steroid hormone antagonists
were added either before or after injury. In female cortical explants, pretreatment
or post-treatment with any of the sex steroid hormones did not remove the E2
mediated protection following 2DG/KCN treatment. Interestingly, treatment with
the inhibitors alone provided additional protection for the female explants
following injury with 2DG/KCN. This did not confirm our initial hypothesis that if
E2 neuroprotection in female cortical explants is mediated by a particular
receptor, blocking that receptor will increase cell death and remove the E2
mediated protection. In fact, most inhibitors further reduced cell death in the
2DG/KCN (injury) treated female explants, results summarized in Table 4.1. The
hypothesis for the male cortical explants that these receptors are also aiding in
the cell death caused by 2DG/KCN, was confirmed and summarized in Table 4.2.
Interestingly, male cortical explants followed a similar pattern of protection when
the sex steroid hormone receptors were inhibited.
In female explants treated with MPP, an ER! antagonist, the drug did
affect cell death. However, this affect was not what we predicted. In the
2DG/KCN injured explants, addition of 1 uM MPP prior or 6 hours after the injury
decreased cell death. We predicted that blocking ER! would actually increase
cell death if E2 were acting via ER!. Interestingly, pre-treatment with MPP to the
non-injured explants actually increased cell death, suggesting the drug is having
Table 4.1. Summary of the Role of Sex Steroid Hormone Receptor Activity.
24 hour pre-treatment and 6 hour post-treatment with ER!, ER" and AR
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antagonist in female cortical explants injured with 2DG/KCN. Note: ! indicates
an increase in cell death, " indicates a decrease in cell death and V indicates
vehicle (no drug).
Cell Death
Non Injured

! from V non-injured

2DG/KCN

" from V 2DG/KCN

Non Injured

" from V 2DG/KCN

2DG/KCN

" from V 2DG/KCN

Non Injured

! from V non-injured
" from V 2DG/KCN

2DG/KCN

" from V 2DG/KCN

Non Injured

" from V 2DG/KCN

2DG/KCN

" from V 2DG/KCN

Non Injured

" from V 2DG/KCN

2DG/KCN

" from V 2DG/KCN

Non Injured

! from V non-injured

2DG/KCN

" from V 2DG/KCN

Non Injured

No Effect

2DG/KCN

! from V non-injured

Non Injured

" from V 2DG/KCN

2DG/KCN

" from V 2DG/KCN

Non Injured

" from V 2DG/KCN

2DG/KCN

" from V 2DG/KCN

MPP
24 Hour
PreTreatment

PHTPP

Flutamide

MPP
Female
Cortical
Explants

1 uM 6
Hour
PostTreatment

PHTPP

Flutamide

MPP
1 nM 6
Hour
PostTreatment

PHTPP

Flutamide
Table 4.2. Summary of the Role of Sex Steroid Hormone Receptor Activity.
24 hour pre-treatment and 6 hour post-treatment with ER!, ER" and AR
antagonist in male cortical explants injured with 2DG/KCN. Note: ! indicates an
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increase in cell death, ! indicates a decrease in cell death and V indicates
vehicle (no drug).
Cell Death
Non Injured

No Effect

2DG/KCN

" from V non-injured

Non Injured

No Effect

2DG/KCN

" from V non-injured

Non Injured

! from V 2DG/KCN

2DG/KCN

! from V 2DG/KCN

Non Injured

No Effect

2DG/KCN

No Effect

Non Injured

" from V non-injured

2DG/KCN

" from V non-injured

Non Injured

No Effect

2DG/KCN

! from V 2DG/KCN

Non Injured

No Effect

2DG/KCN

" from V non-injured

Non Injured

" from V 2DG/KCN

2DG/KCN

" from V 2DG/KCN

Non Injured

! from V 2DG/KCN

2DG/KCN

! from V 2DG/KCN

MPP
24 Hour
PreTreatment

PHTPP

Flutamide

MPP
Male
Cortical
Explants

1 uM 6
Hour
PostTreatment

PHTPP

Flutamide

MPP
1 nM 6
Hour
PostTreatment

PHTPP

Flutamide
an effect even when there is no injury. When cell death was evaluated in all 3
scenarios, pre or post treatment with MPP, 2DG/KCN did not induce significant
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injury. This indicated that when MPP is present before or after 2DG/KCN
treatment, a significantly injury cannot be induced.
Treatment with 1 uM PHTPP (ER! antagonist) 24 hours before or 6 hours
following injury also caused a significant decrease in cell death in the 2DG/KCN
injured explants. Interestingly a lower concentration, 1 nM, of PHTPP increased
cell death, regardless of a 2DG/KCN injury, when added 6 hours following injury.
Treatment with Flutamide, the AR antagonist, also significantly decreased
cell death in the 2DG/KCN treated and an increase in cell death in the noninjured when the inhibitor was added 24 hours before injury. Post-treatment with
the two different concentrations did result in significant differences. Posttreatment with Flutamide increased cell death in the non-injured at 1 um, but not
1 nM. There was a significant decrease in the 2DG/KCN injured groups when
post-treated with Flutamide.
In male cortical explants, MPP either pre or post-treatment did not affect
cell death in the non-injured. 2DG/KCN increased cell death in the pre-treatment
and 1 nM post-treatment from the vehicle non-injured. Pre-treatment with
PHTPP also did not influence cell death in the non-injured, but did decrease cell
death in the 2DG/KCN injured. Post-treatment with PHTPP regardless of
concentration and injury increased cell death from the vehicle non-injured.
However, Flutamide pre and post treatment decreased cell death from the
vehicle 2DG/KCN injured; except for the 1 uM post-treated non-injured, which did
not have an effect.
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The increase in cell death in the non-injured female explants could
indicate that these receptors are needed at a certain concentration to maintain a
healthy explant and by inhibiting these receptors the explant loses its cellular
regulation. The exact roles of these sex steroid hormone receptors are not well
defined. Since these receptors are located in the mitochondria, (Solakidi, Psarra
et al. 2005; Arnold and Beyer 2009; Vasconsuelo, Pronsato et al. 2011) they may
be necessary for transcription of mitochondrial genes. There are 37 genes
contained in the mitochondrial DNA, some of which encode enzymes for the
oxidative phosphorylation. Disruption of the mitochondrial sex steroid hormone
receptors may disrupt the electron transport chain by down regulating the
transcription of oxidative phosphorylation enzymes needed to maintain normal
cellular respiration and homeostasis.
Another possible reason for the additional damage is that the inhibitor
cocktail itself is damaging to the explant and somehow prevents additional injury
when the explants are treated with 2DG/KCN. However, because the effects of
each inhibitor were dependent on the concentration and timing of treatment, it is
unlikely the inhibitor cocktail but rather a base-line concentration of receptors are
needed.
In summary, female cortical explants had an effect of E2 with posttreatment of PHTPP at 1uM and pre-treatment with Flutamide. Post-treatment of
1 uM PHTPP inhibited cell death induced by 2DG/KCN in the E2 pre-treated
female explants. However, EtOH (controls) did have a significant increase in cell
death with 2DG/KCN. E2 pre-treatment increased cell death. Pre-treatment with
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Flutamide, also had an increase with 2DG/KCN in the EtOH group and E2
protected this increase. Interestingly, E2 pre-treatment did not influence cell
death in male cortical explants treated with antagonist or injured with 2DG/KCN.
This correlates to the protective effect of E2 in female, but not male cortical
explants. We initially hypothesized that if E2 neuroprotection in female cortical
explants is mediated by a particular receptor, blocking that receptor will increase
cell death and remove the E2 protection. We did not find any data to support that
hypothesis. In fact, most inhibitors further reduced cell death when injured with
2DG/KCN.
Overall, the E2 mediated protection seen in female cortical explants was
not mediated through ER!, ER" or AR in a classical fashion. In fact, when these
receptors were inhibited in female cortical explants there was a decrease in cell
death in the 2DG/KCN injured. In female cortical explants, blocking ER!, ER" or
AR following injury with 2DG/KCN did not add additional cell death to the noninjured, depending on the antagonist and the concentration. In male cortical
explants, 2DG/KCN caused significant cell death in the MPP scenarios from the
vehicle non-injured. PHTPP post-treatment generally increased cell death from
the vehicle non-injured. However, PHTPP pre-treatment and Flutamide pre and
post-treatment decreased cell death from the vehicle 2DG/KCN injured. These
results are extremely perplexing. Concentration and timing of the antagonist
influences cell death, indicating different roles of the specific sex steroid hormone
receptors throughout protection and injury in both female and male cortical
explants.
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These data indicate that sex steroid hormone receptors may play a role in
the ability of 2DG/KCN to induce injury. Only treatment with 2DG/KCN induces a
significant injury with in the vehicle group. Studies have shown that ER!, ER"
(Solakidi, Psarra et al. 2005; Pedram, Razandi et al. 2006; Arnold and Beyer
2009; Vasconsuelo, Pronsato et al. 2011) and AR (Solakidi, Psarra et al. 2005)
are present in the mitochondria. KCN in our injury inhibits oxidative
phosphorylation by inhibiting cytochrome c oxidase in complex IV of the electron
transport chain (ETC). E2 mediated protection in another injury models,
hemorrhagic shock, was mediated through ER" in the mitochondria by
upregulating the genes of complex IV in the ETC (Hsieh, Yu et al. 2006).
Disruption of complex IV by cyanide (CN-) treatment inhibited the E2 mediated
protection (Hsieh, Yu et al. 2006). E2 also increased expression of ER! and
ER" in the mitochondria (Chen, Delannoy et al. 2004; Chen, Eshete et al. 2004).
Since E2 can increase expression of ER in the mitochondria where there is a
balance of normal cellular respiration from the ETC, in our model the balance of
hormone receptors could be such that when E2 is present and the explants are
injured, E2 is able to compensate for the inhibition of cytochrome c oxidase and
mediate protection. However, when we potentially disrupt the activity of these
sex steroid hormone receptors in the mitochondria we can see an increase in cell
death without the addition of 2DG/KCN that could be interfering with our injury or
inducing secondary pathways to maintain a homeostatic environment. Our
results are timing and concentration specific when we do not see additional cell
death to the non injured and can further reduce injury in the 2DG/KCN treated.
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Sex steroid hormones receptors may have additional roles in the mitochondria,
which allow additional protection from injury or increase cell death in a basal (non
injured) state regardless of E2 treatment when these receptors are inhibited.
Cell survival can be promoted through genomic and non-genomic actions of
steroid hormone receptors. E2 can have both genomic and non-genomic actions
on target tissues by binding to the well-characterized steroid hormone receptors,
ER! and ER" (Green, Kumar et al. 1986; Koike, Sakai et al. 1987; Kuiper,
Enmark et al. 1996; Berne RM 2004). Androgens, testosterone and
dihydrotestosterone, have important actions by binding to AR (Roy, Lavrovsky et
al. 1999). ER!, ER" and AR are steroid hormone receptors located not only in
the nucleus, but also the plasma membrane, cytosol and mitochondria (Speroff
2000; Gonzalez, Cabrera-Socorro et al. 2007). AR expression is localized with
ER! and ER" expression in many areas of the brain, specifically the cortex and
hypothalamus (Patchev, Schroeder et al. 2004).
Sex steroid hormones can have both genomic and non-genomic actions on
target tissues (Murdoch and Gorski 1991; Berne RM 2004). Here we have
eliminated the role of E2 working through the classical genomic pathways in our
model of E2-mediated neuroprotection. The non-genomic actions of steroid
hormones include membrane initiated signaling pathways that are activated not
only by ER!, ER" and GPR30 (Watson, Jeng et al. 2008; Roman-Blas,
Castaneda et al. 2009; Liu, Zhang et al. 2012), but by AR (Foradori, Weiser et al.
2008) (Peterziel, Mink et al. 1999). E2 induces phosphorylation of extracellular
signal-regulated kinase (ERK1/2) (Singh, Setalo et al. 1999; Setalo, Singh et al.
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2002; Liu, Zhang et al. 2012). ERK is a part of the mitrogen-activated protein
(MAP) kinase pathway (Singer, Figueroa-Masot et al. 1999; Watson, Jeng et al.
2008). Another second messenger signaling pathway that can be activated is
the serine/threonine protein kinase, AKT, through the phosphatidylinositide 3’OH
kinase (PI3 K) by E2 (Datta, Brunet et al. 1999; Wilson, Liu et al. 2002) and
testosterone (Yu, Akishita et al. ; Yu, Akishita et al.). These kinases regulate a
number of cellular responses including cell death (Yu, Akishita et al. ; Yu,
Akishita et al. ; Lee and McEwen 2001; Murphy and Blenis 2006). Activation of
one or more of these signaling cascades by E2 can promote cell survival. In our
studies, these non-genomic actions of E2 may be responsible for our results.
These data are the first to show that E2 mediated protection is not
mediated through ER!, ER" or AR in the classical receptor mediated fashion. In
fact, depending on concentration and timing of the antagonist, ER!, ER" and AR
antagonist could reduce cell death following treatment with 2DG/KCN with out
affecting the non-injured explants. The specific roles of sex steroid hormone
receptors to increase injury have not been described in the female or male
cortex. These data demonstrate that cortical responses to injury may be innate
and preprogrammed based on sex and hormonal background.

!

181

CHAPTER 5: GENERAL DISCUSSION

Summary
The studies included in this dissertation provide valuable insight into how
sex steroid hormone receptors in the cortex respond during early postnatal
development and following injury. The isocortex is a nonconventional area of the
brain to study sex steroid hormone receptor dynamics. These receptors have
been studied more extensively in other regions of the brain, such as the
hypothalamus, that are responsible for the reproductive action of steroids.
Estrogen and androgens are two main sex steroid hormones that are associated
with sex differences. ER!, ER" and AR are the typical sex steroid hormone
receptors associated with estrogens and androgens. It is important to
understand expression of these receptors in the cortex at the time of injury to see
how these receptors respond to injury.
During cortical development, the expression of several sex steroid
hormones was dynamic. ER! mRNA expression was elevated then decreased to
a very low level across early postnatal development. ER" and AR mRNA
expression were low and then increased across early postnatal development in
the cortex. Interestingly, around the same time the changes in sex steroid
hormone receptors occur in the cortex, steroidogenesis is beginning in the
female and male sex organs, ovaries and testes. Reproductive regions of the
brain respond to steroidogenesis by up or down regulating receptors and
signaling cues to establish a positive and negative feedback loop to regulate the
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reproductive axis. Although the cortex is normally not thought of as being
reproductively dynamic, it may also respond to changes in the hormone milieu.
Interestingly, although females and males have different sex organs and different
primary sex hormones, estrogen for females and testosterone for males, there
was no sex difference in how ER!, ER" or AR mRNA expression changed
across early postnatal development. The fact that ER! mRNA expression is high
then decreases and ER" and AR mRNA expression are low then increase in
both the female and male cortex across early postnatal development suggest a
role for ER" and AR in the adult cortex.
Cortical explants were used to evaluate the innate changes that occur as
the cortex “ages” across time in culture because this in vitro model maintains the
neuronal/glial cross talk and cellular cytoarchitectural organization of the cortex.
During early postnatal development ER!, ER" and AR expression are dynamic in
the intact cortex. To evaluate whether these changes are innate to the cortex
during development or require input from other brain regions we measured sex
steroid hormone receptor mRNA expression in cortical explants across time in
culture. Female and male cortical explants were plated in either EtOH (vehicle)
or E2 to evaluate the innate changes of these sex steroid hormone receptors that
occur within the cortex and also to determine the affects of E2 on these receptors
across time in culture. ER! mRNA expression was high then decreased while
ER" and AR mRNA expression were low then increased across time in culture in
both female and male cortical explants. Interestingly, treatment with E2 only had
an affect on ER! mRNA expression in male cortical explants across time in
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culture. Here the changes in sex steroid hormone receptor mRNA expression
that occurred in cortical explants were similar to the pattern of changes that we
see in the intact cortex. These data are the first to show that regulation of steroid
hormone receptors in the rat cortex is innate and still occurs when it is isolated
from other brain regions.

Changes in sex steroid hormone receptors following injury
Another time-point where sex steroid receptors are known to change is in
the cortex following an injury. 24 hours after MCAO, ER! mRNA and protein are
increased in the cortex of female rats and mice (Dubal, Shughrue et al. 1999;
Dubal, Rau et al. 2006). In OVX females, the increase in ER! mRNA occurs in
both oil and E2-treated groups, but is seen earlier after injury with E2 (Dubal,
Rau et al. 2006). E2 treatment also attenuates the decrease in ER" seen
following injury in the oil treated females (Dubal, Rau et al. 2006). Interestingly in
gonadally-intact males, ER! does not increase following injury. Since there are
sex-specific changes in sex steroid hormone receptors in the intact brain
following injury, I evaluated these sex steroid hormone receptors in my cortical
explant model to determine if these changes will occur in a sex specific manner
and are innate to the cortex.
The cortical explant model allowed us to investigate sex differences
following injury in the cortex while maintaining the important neuron/glia
connections and cross talk that other models lose by isolating and culturing either
neurons or glia cells. Ischemia can be induced in cortical explants by applying

!

184

2DG/KCN to block glycolysis and oxidative phosphorylation, which are the two
main areas that become disrupted during ischemic stroke. In my studies, I found
that the time-course of cell death was different in female versus male cortical
explants. Female cortical explants had significant injury with 2DG/KCN treatment
at 24 hours. However, male cortical explants had significant injury at 12 hours,
but the relative levels of injury were similar to females. Differences in the cell
death time-course between females and males indicate males may be more
susceptible to chemical induced ischemia than females. Interestingly, in a
mouse model of traumatic brain injury (TBI), cell death occurs faster and at a
higher magnitude in males than females (Roof, Duvdevani et al. 1993; Roof and
Hall 2000; Bramlett and Dietrich 2001).
There was also a sex difference in the way that the explants responded to
injury after the addition of E2. E2 attenuated cell death in female, but not male
cortical explants. In contrast, following MCAO, male rats do experience
additional protection with the addition of E2 following MCAO (Toung, Traystman
et al. 1998; Saleh, Cribb et al. 2001; Saleh, Cribb et al. 2001). It would appear
that these males were only protected by E2 when the cortex had inputs from
other regions of the brain. It is also possible that the difference in the cell death
in the two different paradigms may also account for the differences in response
to cell death. These studies together indicate that the cortex may be organized
differently in females and males, and that E2 may work via a sex-specific
mechanism. In the female, E2 mediated protection is innate to the cortex, where
E2 mediated protection in males is not and requires outside inputs.
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Another possible reason for the sex difference in cell death with E2
pretreatment is that males require a higher concentration of E2 for protection. E2
mediated protection in females is at physiological concentrations and requires
pretreatment for 7 days indicating that this protection may be through the
classical genomic pathways for sex steroid hormones. However, since males are
not protected at physiological concentrations and may required pharmacological
concentrations to exert protection indicates that E2 in males may have
antioxidant effects by reducing reactive oxygen, rather than receptor mediated
effects.

Changes in ER! mRNA expression in cortical explants following injury
In female rat explants, E2 was protective following treatment with
2DG/KCN. These results are similar to the protective effect of E2 following
MCAO. In the MCAO model, an increase in ER! is essential for E2-mediated
protection in female rats (Suzuki, Brown et al. 2007). Interestingly, ER! also
changed in female cortical explants following 2DG/KCN treatment, but E2
treatment prevented this increase. Not surprisingly, the increase in ER! mRNA
expression occurred at a different time following injury in explants versus in the
intact cortex. Following MCAO, ER! mRNA expression began to increase at 4
hours, where it peaked, and continued to remain significantly increased out to 24
hours. In female cortical explants, ER! mRNA expression was significantly
increased at 8 hours, but had returned to baseline by 24 hours after injury. ER!
mRNA also returns to baseline following MCAO (unpublished observations), but
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it takes a longer period of time. These data suggest that ER! mRNA responses
to injury may be innate to the cortex, although the time-course for expression is
different in each model.
The difference in the time-course for changes in ER! mRNA could be
attributed to the baseline expression of ER! before injury. Interestingly, ER!
mRNA expression is virtually absent in the adult rodent cortex and increases
following injury. However, in cortical explants there is a higher baseline
expression of ER! mRNA expression at the time of injury and only the vehicle
(EtOH)-treated female cortical explants respond to injury by increasing ER!
mRNA expression. Because there was an increase in cell death in the vehicletreated female explants (compared to E2) and an increase in ER! mRNA
expression, it is possible that the E2 protects the female cortical explants by
inhibiting an increasing in ER! mRNA expression. The levels of ER! mRNA are
not different between EtOH and E2-treated female cortical explants across time
in culture, specifically at the time of injury (PND10), suggests that E2 does not
affect the baseline expression of ER! mRNA. However, E2 does inhibit ER!
mRNA expression from increasing following injury in the cortical explant model,
which is protective.

Changes in ER" mRNA expression in cortical explants following injury
Following MCAO in female rat cortex, ER" mRNA expression is initially
elevated and then dramatically declines by 16 and 24 hours (Dubal, Rau et al.
2006). Pretreatment with E2 prevents the injury-induced decrease in ER" at 16
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and 24 hours after injury (Dubal, Rau et al. 2006). Here, ER! mRNA expression
did not change in either EtOH or E2-treated female or male cortical explants
following treatment with 2DG/KCN. This difference in how ER! responds to
injury in the cortical explant model (in vitro) versus the MCAO model (in vivo)
may reflect differences between the two injury paradigms or could indicate an
influence of other brain regions that is lost in the explants. These data are very
interesting because E2 does not decrease cell death following MCAO in ER"
knock out mice, but does in ER! knock out mice suggesting ER" is necessary to
mediate E2 protection. However, it is possible that the two receptors are working
together to mediate E2 neuroprotection when in homeostasis. Since ER! may
require feedback or connections from other brain regions it is possible that those
regions are able to still send signaling cues even when ER! is removed.
However, since ER" appears to be regulated mainly with the cortex it is unable to
compensate and E2 neuroprotection is lost in ER" knockouts.

Changes in AR mRNA expression in cortical explants following injury
There was a sex difference in the way AR mRNA expression responded to
injury. In both EtOH and E2-treated female explants, AR mRNA was significantly
increased at 8 hours following treatment with 2DG/KCN was decreased by 24
hours. There was no increase in AR mRNA expression in males at any time
point following treatment with 2DG/KCN. These data are the first to demonstrate
sex specific changes in AR in following injury. AR responds similarly to
2DG/KCN treatment in EtOH and E2 treated female explants, indicating that
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changes in AR mRNA are in response to injury rather than E2 mediated
protection. While changes in AR mRNA or protein have not been evaluated
following injury, the role of AR in protection has been evaluated. Interestingly,
males, not females (Kitano, Young et al. 2007), showed AR-dependent protection
with isoflurane preconditioning following MCAO (Zhu, Wang et al. 2010).
Flutamide, an AR antagonist, removed the protection of isoflurane precondition in
male rats that have undergone MCAO (Zhu, Wang et al. 2010). AR has also
been suggested to mediate the effects of androgens and neuroprotection
(Uchida, Palmateer et al. 2009). There is a difference in the role AR plays in
injury in the cortical explant model (in vitro) verse the MCAO model (in vivo).
Flutamide decreased cell death in 2DG/KCN-treated female and male cortical
explants depending on timing and concentration of the drug. However, Flutamide
increased cell death in male rats following MCAO (Uchida, Palmateer et al.
2009)(Zhu, Wang et al. 2010). Since AR increases cell death following injury in
the cortex when there are synapses and connections to other brain regions and
decreases cell death when the cortex is isolated in culture could indicate that AR
in the cortex are influenced from other regions of the brain.

Inhibiting ER!, ER" and AR
If ER!, ER" or AR is playing a role in E2 mediated protection then
inhibiting that receptor should remove the protection. To evaluate the role of
ER!, ER" and AR selective antagonists were chosen to inhibit each receptor,
MPP, PHTPP and Flutamide, respectively. Because we did not see the level of
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cell death we anticipated when the inhibitors were added before the injury, we
were concerned that the drug in the culture media before injury may be
influencing the ability of 2DG/KCN to induce cell death. To eliminate this
problem, we included two additional paradigms where inhibitor drugs were added
following injury.
In female explants, only the vehicle (non antagonist) treated group had
significant cell death when treated with 2DG/KCN. As expected, E2 attenuated
this cell death in female cortical explants. 2DG/KCN did not induce a significant
injury in any of the drug groups and depending on concentration and timing cell
death was further reduced in the 2DG/KCN group. A tight regulation of sex
steroid hormone receptors may be occurring because addition of the inhibitors
alone caused additional cell death without 2DG/KCN treatment. These data
suggest that if receptor function is too high or too low additional injury can result,
indicated by the increase in cell death in the non-injured explants. These data
indicate ER! and AR, but not ER", may play a role in the injury induced by
2DG/KCN in female cortical explants.
The male cortical explants also only had significant cell death with
2DG/KCN treatment in the vehicle group. E2 did not attenuate cell death in male
cortical explants. 2DG/KCN did not induce a significant injury in any of the drug
groups and depending on concentration and timing cell death was further
reduced in the 2DG/KCN group. These data indicate that ER", ER! and AR may
play a role in the injury induced by 2DG/KCN in male cortical explants.
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The initial goal of determining which receptor was responsible for the E2mediated protection was not obtained. In fact, significant cell death was not
obtained when the explants were treated with 2DG/KCN in the presence of an
antagonist for sex steroid hormone receptors. These antagonists may cause off
target effects that are not directly related to blocking the specific sex steroid
receptor. Off target effects have been reported with other antagonist in clinical
trials (Miyazawa 2011). Specific off target effects have not been reported with
these antagonists; however, sex steroid hormone membrane receptors or ion
channels could have been activated without our knowledge. These off target
effects can be beneficial or detrimental and may lead to misinterpretation of
experimental results.
MPP, ER! antagonist, is a selective silent antagonist that blocks the
activity of ER! at the receptor level and does not have any intrinsic activity to
activate the ER! receptor. This receptor antagonist may affect other signaling
pathways or proteins with in the cell. Since 2DG/KCN treatment did not cause
significant cell death when MPP, along with PHTPP and Flutamide, were present
these antagonist may activate cell survival pathways that disrupts 2DG/KCN’s
ability to cause cell death. These antagonists may also disrupt the cell death
pathways by disrupting the cells ability to undergo apoptosis, possibly by
decreasing cytochrome c or disrupting caspase cell death pathways.
The pathways of cell death may be different for females and males. In
females, the caspase cascade, a family of cysteine proteases that are involved in
apoptotic cell death, is believed to play a major role in cell death following injury
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(Renolleau, Fau et al. 2007). Inhibition of this cascade attenuates cell death in
female, but not male rodents following MCAO (Renolleau, Fau et al. 2007).
However, the poly (ADP-ribose) polymerase-1, an enzyme involved in DNA

repair, inhibition in males is protective, but not in females following MCAO
(Hagberg, Wilson et al. 2004). The difference in cell death pathways that occur in
vivo, following MCAO, may add insight to sex difference in cell death in the
cortical explant model. It is important to note that these two models are different
types of ischemic injuries. Cell death in the cortex following MCAO is largely
secondary to the primary death that occurs in the striatum. 2DG/KCN injury is
directly applied to the cortex and this injury is considered primary.
From these data we can correlate that there is an effect of sex steroid
hormone receptors in injury because we could not reach a significant injury with
2DG/KCN in drug groups. Only treatment with 2DG/KCN induced a significant
injury within the vehicle group. Studies have shown that ER!, ER" (Solakidi,
Psarra et al. 2005; Pedram, Razandi et al. 2006; Arnold and Beyer 2009;
Vasconsuelo, Pronsato et al. 2011) and AR (Solakidi, Psarra et al. 2005) are
present in the mitochondria. KCN in our injury inhibits oxidative phosphorylation
by inhibiting cytochrome c oxidase in complex IV of the electron transport chain
(ETC). E2 mediated protection in another injury models, hemorrhagic shock,
was mediated through ER" in the mitochondria by upregulating the genes of
complex IV in the ETC (Hsieh, Yu et al. 2006). Disruption of complex IV by
cyanide (CN-) treatment inhibited the E2 mediated protection (Hsieh, Yu et al.
2006). E2 also increased expression of ER! and ER" in the mitochondria
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(Chen, Delannoy et al. 2004; Chen, Eshete et al. 2004). Since E2 increases
expression of ER in the mitochondria where there is a balance of normal cellular
respiration from the ETC, in our vehicle model the balance of hormone receptors
is such that when E2 is present and the explants are injured with CN- that E2 is
able to compensate for the inhibition of cytochrome c oxidase and mediate
protection.
The disruption of the activity level of some of these sex steroid hormone
receptors in the mitochondria caused an increase in cell death without the
addition of 2DG/KCN. The increase in cell death in the non-injured female and
male explants could indicate that these receptors are needed at a certain activity
level to maintain a healthy explant. Another possible reason for the additional
damage is that the inhibitor cocktail itself is damaging to the explant and some
how prevents additional injury when the explants are treated with 2DG/KCN.
However, because there effect was dependent on the concentration and timing of
treatment of the antagonist, it is unlikely the inhibitor cocktail cause damage but
rather a base line activity level of receptors are needed.
ER!, ER" and AR mRNA expression did not change in male cortical
explants following 2DG/KCN treatment. ER! and ER" mRNA expression also
did not change in response in injury in the male brain in vivo (Broughton, Brait et
al. 2012). AR mRNA has not been evaluated following injury in the cortex.
However, another estrogen receptor, GPR30, has been recently evaluated
following a 30 minutes transient MCAO in OVX females and gonadally intact
female and male mice (Broughton, Brait et al. 2012). Interestingly, in male mice
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there is an increase in GPR30 4 hours following MCAO that returned to baseline
at 24 hours (Broughton, Brait et al. 2012). In the same studies, there were no
significant changes in ER! or ER" at 4 or 24 hours post injury (Broughton, Brait
et al. 2012). These data suggest that GPR30 responds to injury in the male, but
not the female cortex. Here we did evaluate changes in GPR30 mRNA
expression 24 hours following 2DG/KCN treatment in both female and male
cortical explants. We did not see any change in GPR30 mRNA expression at 24
hours following injury (unpublished observations), but it is possible that there was
a GPR30 response that we missed by only looking at 24 hours. It is possible that
the increase occurred early was only transient (as was seen with ER! and AR in
females).

Potential Models
In our 2DG/KCN cortical explant model, cell damage is caused by
inhibiting glycolosis and also disrupting oxidative phosphorylation in the
mitochondria, which may increase cytochrome c release activating an intrinsic
pathway of cell death. Cell death can occur extrinsically or intrinsically in the
mitochondria. The extrinsic cell pathway, also called the “death receptor
pathway,” is activated when “death receptors” such as tumor necrosis factor
(TNF) receptor or the TNF-related apoptosis inducing ligand (TRAIL) receptors
become activated and signal Caspase-8 (Kroemer, Galluzzi et al. 2007).
Caspase-8 can activate additional caspases that lead to apoptosis, such as
Caspase-3 to 6 to 7, or can activate a pro-apoptotic Bcl-2 protein (BID) (reviewed
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in (Kroemer, Galluzzi et al. 2007). BID can induce the intrinsic pathway by
interacting with Bax, another Bcl-2 protein, causing mitrochondrial outer
membrane permeabilization (Wang, Yin et al. 1996). This permeabilization
releases cytochrome c and other pro-apoptotic factors that induce additional
caspases, which leads to cell death (Figure 5.1). The intrinsic pathway can also
be activated by DNA or damage to the cell (Kroemer, Galluzzi et al. 2007).
In our cortical explant model of ischemia, E2 does not appear to act via
the classic receptor mediated mechanism of protection. E2 can activate many
organelles in the cell, such as the cytoplasm, nucleus and the mitochondria. One
mechanism of E2-mediated protection is through steroid hormone receptors.
However, when we added antagonist to inhibit these receptors in our model,
2DG/KCN was not able to cause significant cell death that we normally see when
no antagonist is added. In the vehicle group (no antagonist), 2DG/KCN induced
significant injury in both female and male cortical explants and E2 attenuated this
cell death in females. These data suggest that E2 is not working through ER!,
ER" or AR to mediate protection. Our proposed model of E2 mediated
protection in cortical explants is diagramed in Figure 5.2. E2 can bind to
receptors on the membrane, such as GPR30, tyrosine kinase receptors, or
growth factor receptors. These receptors become activated and signal to
downstream signaling pathways to promote cell survival. For example, E2 has
been shown to activate AKT by phosphorylation, pAKT (Wilson, Liu et al. 2002).
pAKT can signal down stream to increase cell survival proteins. pAKT could also
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activate transcription of genes to produce more membrane receptors, GPR30.
E2 binds to GPR30, which activates more PI3K that phosphorylates more AKT.
E2 mediated protection was not removed when ER!, ER" or AR was
inhibited. In fact, treatment with these inhibitors decreased cell death in the
2DG/KCN treated explants. This decrease in cell death with the inhibitors was
not affected by the presence of E2. Since inhibiting the receptors decreased cell
death, it is possible that KCN may be interacting with sex steroid hormones
receptors, Figure 5.1. ER! and ER" can be found in the mitochondria, but very
little is know about their location or function. KCN acts by disrupting complex IV
of the ETC in the mitochondria, I hypothesize that there are sex steroid hormone
receptors near that complex that can interfere with how KCN disrupts complex
IV. Since very little is know about the location of these receptors and there
function in the mitochondria, they could not only aide in regulating mitochondria
genes necessary for the electron transport chain but could also affect how
cytochrome C is released to trigger cell death.
These data are the first to show that E2 mediated protection following
2DG/KCN injury is not mediated through ER!, ER" or AR. In fact, depending on
concentration and timing of the antagonist, ER" and AR antagonist could reduce
cell death following treatment with 2DG/KCN without affecting the non-injured
explants. These data demonstrate that cortical responses to injury are innate
and preprogrammed based on sex and hormonal background. The role of sex
steroid hormone receptors in injury needs to be further evaluated along with
mechanism of sex differences in cell death.
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Figure 5.1 Diagram of 2DG/KCN injury in cortical explants. 2DG/KCN blocks
glycolyosis and oxidative phosphorylation. 2DG is a glucose molecule that has a
hydrogen in place of a hydroxyl group. Hexokinase traps this modified glucose
molecule in the cell by converting 2DG to 2DG-P. This molecule cannot continue
in glycolysis because phosphoglucose isomerase (PGI) cannot use 2DG-P as a
substrate (Brown 1962; McComb and Yushok 1964; Parniak and Kalant 1985;
Karczmar, Arbeit et al. 1992). KCN inhibits cytochrome c oxidase in the
mitochondrial electron transport chain by binding to the iron in cytochrome c so
that cytochrome c oxidase is unable to transfer electrons to oxygen. This
disruption inhibits the ETC from producing ATP.
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activate a kinase cascade that up-regulate cell survival proteins.
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